| Fertility and Sterility | 86.1 | 3 | 3 |
| Prelude Fertility | 68.9 | 3 | 1 |
| Pacific Fertility Center Los Angeles (PFCLA) | 68.9 | 3 | 1 |
| Mayo Clinic | 60.0 | 4 | 0 |
| LoopNet | 60.0 | 4 | 0 |
| Human Resource Management Review | 60.0 | 4 | 0 |
| Midwest Fertility Specialists | 58.2 | 2 | 1 |
| Colorado Center for Reproductive Medicine | 58.2 | 2 | 1 |
| Sher Fertility | 58.2 | 2 | 1 |
| National Institute for Occupational Safety and Health | 51.7 | 3 | 0 |
| Brain and Language | 51.7 | 3 | 0 |
| Virology | 51.7 | 3 | 0 |
| Applied Mathematics and Computation | 51.7 | 3 | 0 |
| Advances in Virus Research | 51.7 | 3 | 0 |
| Advances in Parasitology | 51.7 | 3 | 0 |
| Vital and health statistics. Series 21, Data on natality, marriage, and divorce | 51.7 | 3 | 0 |
| Vital and health statistics. Series 5, Comparative international vital and health statistics reports | 51.7 | 3 | 0 |
| Pacific Fertility Center | 51.7 | 3 | 0 |
| Chronic Diseases and Translational Medicine | 51.7 | 3 | 0 |
| World Journal of Otorhinolaryngology-Head and Neck Surgery | 51.7 | 3 | 0 |
| Office of Readiness and Response | 51.7 | 3 | 0 |
| American Society for Reproductive Medicine | 43.1 | 1 | 1 |
| Reproductive Medicine Associates of New York | 43.1 | 1 | 1 |
| Reproductive Medicine Associates of New Jersey | 43.1 | 1 | 1 |
| Reproductive Medicine Institute | 43.1 | 1 | 1 |
| Wave Motion | 41.0 | 2 | 0 |
| Ultrasonics Sonochemistry | 41.0 | 2 | 0 |
| Massachusetts General Hospital | 41.0 | 2 | 0 |
| Nucleic Acids Research | 41.0 | 2 | 0 |
| Q229883 | 41.0 | 2 | 0 |
| Clinical Genitourinary Cancer | 41.0 | 2 | 0 |
| Journal of Economic Theory | 41.0 | 2 | 0 |
| Blood | 41.0 | 2 | 0 |
| Tetrahedron Letters | 41.0 | 2 | 0 |
| Nuclear Physics | 41.0 | 2 | 0 |
| Trends in Cell Biology | 41.0 | 2 | 0 |
| Intelligence | 41.0 | 2 | 0 |
| Journal of Operations Management | 41.0 | 2 | 0 |
| Brachytherapy | 41.0 | 2 | 0 |
| Mechanisms of Ageing and Development | 41.0 | 2 | 0 |
| Trends in Cardiovascular Medicine | 41.0 | 2 | 0 |
| Seminars in Cancer Biology | 41.0 | 2 | 0 |
| Journal of Crystal Growth | 41.0 | 2 | 0 |
| Field Crops Research | 41.0 | 2 | 0 |
| Cardiovascular Pathology | 41.0 | 2 | 0 |
| Biophysical Journal | 41.0 | 2 | 0 |
| Physica C | 41.0 | 2 | 0 |
| Computer Communications | 41.0 | 2 | 0 |
| Robotics and Autonomous Systems | 41.0 | 2 | 0 |
| Marine Micropaleontology | 41.0 | 2 | 0 |
| Comptes Rendus. Biologies | 41.0 | 2 | 0 |
| Mathematical Biosciences | 41.0 | 2 | 0 |
| International Journal of Medical Informatics | 41.0 | 2 | 0 |
| Postharvest Biology and Technology | 41.0 | 2 | 0 |
| Nuclear Physics A | 41.0 | 2 | 0 |
| Toxicological Sciences | 41.0 | 2 | 0 |
| Toxicology and Applied Pharmacology | 41.0 | 2 | 0 |
| Advances in Agronomy | 41.0 | 2 | 0 |
| Cancer Detection and Prevention | 41.0 | 2 | 0 |
| Cancer Radiothérapie | 41.0 | 2 | 0 |
| Epi Info | 41.0 | 2 | 0 |
| Microelectronic Engineering | 41.0 | 2 | 0 |
| Optical Switching and Networking | 41.0 | 2 | 0 |
| Journal of Communication Disorders | 41.0 | 2 | 0 |
| Agricultural Systems | 41.0 | 2 | 0 |
| Applied Catalysis A: General | 41.0 | 2 | 0 |
| Applied Clay Science | 41.0 | 2 | 0 |
| International Review of Cytology | 41.0 | 2 | 0 |
| International Journal of Obstetric Anesthesia | 41.0 | 2 | 0 |
| Nuclear Physics B | 41.0 | 2 | 0 |
| Annales pharmaceutiques françaises | 41.0 | 2 | 0 |
| Coordination Chemistry Reviews | 41.0 | 2 | 0 |
| Food Chemistry | 41.0 | 2 | 0 |
| Journal of Molecular Structure | 41.0 | 2 | 0 |
| Journal of the American Society for Mass Spectrometry | 41.0 | 2 | 0 |
| Electrochemistry Communications | 41.0 | 2 | 0 |
| Fuel Processing Technology | 41.0 | 2 | 0 |
| Advances in Cancer Research | 41.0 | 2 | 0 |
| Journal of Fluorine Chemistry | 41.0 | 2 | 0 |
| Journal of Pharmaceutical Sciences | 41.0 | 2 | 0 |
| Microporous and Mesoporous Materials | 41.0 | 2 | 0 |
| Progress in Solid State Chemistry | 41.0 | 2 | 0 |
| Radiation Physics and Chemistry | 41.0 | 2 | 0 |
| Rusk Institute of Rehabilitation Medicine | 41.0 | 2 | 0 |
| Vibrational Spectroscopy | 41.0 | 2 | 0 |
| Weill Cornell Medicine | 41.0 | 2 | 0 |
| Physiology & Behavior | 41.0 | 2 | 0 |
| Vacuum | 41.0 | 2 | 0 |
| Cleveland Clinic | 41.0 | 2 | 0 |
| Computers and Electronics in Agriculture | 41.0 | 2 | 0 |
| Advances in Mathematics | 41.0 | 2 | 0 |
| American Journal of Preventive Medicine | 41.0 | 2 | 0 |
| American Journal of Translational Research | 41.0 | 2 | 0 |
| Biomedical Optics Express | 41.0 | 2 | 0 |
| Brain Research | 41.0 | 2 | 0 |
| China Economic Review | 41.0 | 2 | 0 |
| Cultural Diversity and Ethnic Minority Psychology | 41.0 | 2 | 0 |
| dbSNP | 41.0 | 2 | 0 |
| Early Childhood Research Quarterly | 41.0 | 2 | 0 |
| Experimental Hematology | 41.0 | 2 | 0 |
| Geochimica et Cosmochimica Acta | 41.0 | 2 | 0 |
| Journal of Memory and Language | 41.0 | 2 | 0 |
| Journal of Second Language Writing | 41.0 | 2 | 0 |
| Journal of Sound and Vibration | 41.0 | 2 | 0 |
| Journal of the Academy of Nutrition and Dietetics | 41.0 | 2 | 0 |
| Laboratory Investigation | 41.0 | 2 | 0 |
| Learning and Individual Differences | 41.0 | 2 | 0 |
| Magnetic Resonance Imaging | 41.0 | 2 | 0 |
| Museum Management and Curatorship | 41.0 | 2 | 0 |
| Personality and Individual Differences | 41.0 | 2 | 0 |
| Preventing Chronic Disease | 41.0 | 2 | 0 |
| Quaternary Research | 41.0 | 2 | 0 |
| Western Journal of Medicine | 41.0 | 2 | 0 |
| Transplantation Proceedings | 41.0 | 2 | 0 |
| Trends in Amplification | 41.0 | 2 | 0 |
| Ulster Medical Journal | 41.0 | 2 | 0 |
| The AAPS Journal | 41.0 | 2 | 0 |
| Finite Elements in Analysis and Design | 41.0 | 2 | 0 |
| Linear Algebra and its Applications | 41.0 | 2 | 0 |
| Annales de l'Institut Henri Poincare C | 41.0 | 2 | 0 |
| Applied Mathematics Letters | 41.0 | 2 | 0 |
| Applied Numerical Mathematics | 41.0 | 2 | 0 |
| Current Opinion in Genetics & Development | 41.0 | 2 | 0 |
| Journal of Fluency Disorders | 41.0 | 2 | 0 |
| Nonlinear Analysis | 41.0 | 2 | 0 |
| Nuclear Instruments & Methods in Physics Research B | 41.0 | 2 | 0 |
| Rice | 41.0 | 2 | 0 |
| Seminars in Cell & Developmental Biology | 41.0 | 2 | 0 |
| Systems & Control Letters | 41.0 | 2 | 0 |
| NeuroToxicology | 41.0 | 2 | 0 |
| Differential Geometry and its Applications | 41.0 | 2 | 0 |
| Journal of Combinatorial Theory, Series B | 41.0 | 2 | 0 |
| Journal of Mathematical Analysis and Applications | 41.0 | 2 | 0 |
| Journal of Web Semantics | 41.0 | 2 | 0 |
| Pathophysiology | 41.0 | 2 | 0 |
| BJOG: an International Journal of Obstetrics and Gynaecology | 41.0 | 2 | 0 |
| Archives of Gerontology and Geriatrics | 41.0 | 2 | 0 |
| Cryptogamie Bryologie | 41.0 | 2 | 0 |
| Advances in Marine Biology | 41.0 | 2 | 0 |
| BBA: Molecular Basis of Disease | 41.0 | 2 | 0 |
| Global Finance Journal | 41.0 | 2 | 0 |
| Advances in Carbohydrate Chemistry and Biochemistry | 41.0 | 2 | 0 |
| AAPS PharmSciTech | 41.0 | 2 | 0 |
| Brain and Development | 41.0 | 2 | 0 |
| Cryptogamie Algologie | 41.0 | 2 | 0 |
| Aggression and Violent Behavior | 41.0 | 2 | 0 |
| Pediatric Neurology | 41.0 | 2 | 0 |
| General Hospital Psychiatry | 41.0 | 2 | 0 |
| Comparative Immunology, Microbiology & Infectious Diseases | 41.0 | 2 | 0 |
| International Journal of Mental Health Systems | 41.0 | 2 | 0 |
| Advances in Applied Microbiology | 41.0 | 2 | 0 |
| Optometry - Journal of the American Optometric Association | 41.0 | 2 | 0 |
| Journal of Policy Modeling | 41.0 | 2 | 0 |
| Best Practice and Research: Clinical Gastroenterology | 41.0 | 2 | 0 |
| International Journal of Law and Psychiatry | 41.0 | 2 | 0 |
| Prostaglandins and Other Lipid Mediators | 41.0 | 2 | 0 |
| Building and Environment | 41.0 | 2 | 0 |
| Industrial Marketing Management | 41.0 | 2 | 0 |
| Meat Science | 41.0 | 2 | 0 |
| Research in Organizational Behavior | 41.0 | 2 | 0 |
| Fish and Shellfish Immunology | 41.0 | 2 | 0 |
| Journal of Immunological Methods | 41.0 | 2 | 0 |
| Human Pathology | 41.0 | 2 | 0 |
| Comparative Biochemistry and Physiology. Part A: Molecular and Integrative Physiology | 41.0 | 2 | 0 |
| The History of the Family | 41.0 | 2 | 0 |
| Journal of Environmental Management | 41.0 | 2 | 0 |
| Insight | 41.0 | 2 | 0 |
| Business Horizons | 41.0 | 2 | 0 |
| Computers in Human Behavior | 41.0 | 2 | 0 |
| Government Information Quarterly | 41.0 | 2 | 0 |
| Linguistics and Education | 41.0 | 2 | 0 |
| Cryptogamie Mycologie | 41.0 | 2 | 0 |
| Behaviour Research and Therapy | 41.0 | 2 | 0 |
| Advances in Botanical Research | 41.0 | 2 | 0 |
| Journal of Urban Health | 41.0 | 2 | 0 |
| Comptes Rendus. Géoscience | 41.0 | 2 | 0 |
| Neural Development | 41.0 | 2 | 0 |
| Socio-Economic Planning Sciences | 41.0 | 2 | 0 |
| Organizational Dynamics | 41.0 | 2 | 0 |
| The American Journal of Surgery | 41.0 | 2 | 0 |
| Clinical Neurophysiology | 41.0 | 2 | 0 |
| Ocean Engineering | 41.0 | 2 | 0 |
| International Review of Law and Economics | 41.0 | 2 | 0 |
| Nuclear Physics B - Proceedings Supplements | 41.0 | 2 | 0 |
| Revue Europeene de Psychologie Appliquee | 41.0 | 2 | 0 |
| Computers & Graphics | 41.0 | 2 | 0 |
| Journal of African Earth Sciences | 41.0 | 2 | 0 |
| Journal of the Society of Laparoendoscopic Surgeons | 41.0 | 2 | 0 |
| Annual Reports in Medicinal Chemistry | 41.0 | 2 | 0 |
| Comparative Biochemistry and Physiology. Part D: Genomics and Proteomics | 41.0 | 2 | 0 |
| European Journal of Mechanics A - Solids | 41.0 | 2 | 0 |
| Computers and Composition | 41.0 | 2 | 0 |
| Review of Financial Economics | 41.0 | 2 | 0 |
| Maturitas | 41.0 | 2 | 0 |
| Financial Services Review | 41.0 | 2 | 0 |
| Mechanics Research Communications | 41.0 | 2 | 0 |
| Journal of Cultural Heritage | 41.0 | 2 | 0 |
| Clinical Imaging | 41.0 | 2 | 0 |
| Journal of Environmental Sciences | 41.0 | 2 | 0 |
| Journal of Clinical Lipidology | 41.0 | 2 | 0 |
| Journal of Orthopaedics, Trauma and Rehabilitation | 41.0 | 2 | 0 |
| Ticks and Tick-borne Diseases | 41.0 | 2 | 0 |
| The Electricity Journal | 41.0 | 2 | 0 |
| Social Science Research | 41.0 | 2 | 0 |
| Archives of Cardiovascular Diseases Supplements | 41.0 | 2 | 0 |
| National Survey of Family Growth | 41.0 | 2 | 0 |
| National Vital Statistics System | 41.0 | 2 | 0 |
| NIOSH Power Tools Database | 41.0 | 2 | 0 |
| UCLA Health System | 41.0 | 2 | 0 |
| Q20641742 | 41.0 | 2 | 0 |
| Advances in Nutrition | 41.0 | 2 | 0 |
| Morbidity and Mortality Weekly Report: Recommendations and Reports | 41.0 | 2 | 0 |
| Filtration & Separation | 41.0 | 2 | 0 |
| Fundamental and Applied Toxicology | 41.0 | 2 | 0 |
| Journal of the Less Common Metals | 41.0 | 2 | 0 |
| Scripta Metallurgica | 41.0 | 2 | 0 |
| Diseases of the chest | 41.0 | 2 | 0 |
| Chemical health & safety American Chemical Society, Division of Chemical Health and Safety | 41.0 | 2 | 0 |
| Revista paulista de pediatria : orgão oficial da Sociedade de Pediatria de São Paulo | 41.0 | 2 | 0 |
| Behavioral Biology | 41.0 | 2 | 0 |
| The Journal of clinical and aesthetic dermatology | 41.0 | 2 | 0 |
| Alcohol research : current reviews | 41.0 | 2 | 0 |
| Cell Biology International Reports | 41.0 | 2 | 0 |
| Vital & health statistics. Series 3, Analytical and epidemiological studies | 41.0 | 2 | 0 |
| Dermato-endocrinology | 41.0 | 2 | 0 |
| British Heart Journal | 41.0 | 2 | 0 |
| The western journal of emergency medicine | 41.0 | 2 | 0 |
| Prostate international | 41.0 | 2 | 0 |
| Psychiatry | 41.0 | 2 | 0 |
| Mycobiology | 41.0 | 2 | 0 |
| The Lancet Psychiatry | 41.0 | 2 | 0 |
| Advances in food research | 41.0 | 2 | 0 |
| Science in China. Series B, Chemistry, life sciences & earth sciences | 41.0 | 2 | 0 |
| Genetic analysis, techniques and applications | 41.0 | 2 | 0 |
| Journal of the American Pharmaceutical Association | 41.0 | 2 | 0 |
| Vital and health statistics. Series 3, Analytical studies | 41.0 | 2 | 0 |
| Vital and health statistics. Ser. 4, Documents and committee reports | 41.0 | 2 | 0 |
| Vital and health statistics. Series 13, Data from the National Health Survey | 41.0 | 2 | 0 |
| Journal of epilepsy | 41.0 | 2 | 0 |
| Ethology and sociobiology | 41.0 | 2 | 0 |
| Aging trends (Hyattsville, Md.) | 41.0 | 2 | 0 |
| Clinical microbiology newsletter | 41.0 | 2 | 0 |
| NCHS data brief | 41.0 | 2 | 0 |
| Journal of Verbal Learning and Verbal Behavior | 41.0 | 2 | 0 |
| Paediatrics and Child Health | 41.0 | 2 | 0 |
| The Lancet: Diabetes & Endocrinology | 41.0 | 2 | 0 |
| Avian Research | 41.0 | 2 | 0 |
| Alzheimer's & dementia (Amsterdam, Netherlands) | 41.0 | 2 | 0 |
| Cell Chemical Biology | 41.0 | 2 | 0 |
| MMWR supplements | 41.0 | 2 | 0 |
| Clinical neurophysiology practice | 41.0 | 2 | 0 |
| Information and control | 41.0 | 2 | 0 |
| Studies in Logic and the Foundations of Mathematics | 41.0 | 2 | 0 |
| Computing systems in engineering : an international journal | 41.0 | 2 | 0 |
| National Center for Emerging and Zoonotic Infectious Diseases | 41.0 | 2 | 0 |
| Division of Parasitic Diseases and Malaria | 41.0 | 2 | 0 |
| San Diego Fertility Center | 41.0 | 2 | 0 |
| Chronic Disease Prevention and Health Promotion | 41.0 | 2 | 0 |
| Shady Grove Fertility Center | 41.0 | 2 | 0 |
| Cooper Health System | 41.0 | 2 | 0 |
| The Journal of Finance and Data Science | 41.0 | 2 | 0 |
| CaosDB - Research Data Management for Complex, Changing, and Automated Research Workflows | 41.0 | 2 | 0 |
| Fertility Centers of Illinois | 41.0 | 2 | 0 |
| New Hope Fertility Center | 41.0 | 2 | 0 |
| Johns Hopkins Medicine | 41.0 | 2 | 0 |
| Journal of Urban Management | 41.0 | 2 | 0 |
| Journal of Asian Ceramic Societies | 41.0 | 2 | 0 |
| Climate Risk Management | 41.0 | 2 | 0 |
| Information Processing in Agriculture | 41.0 | 2 | 0 |
| Advances in Inorganic Chemistry and Radiochemistry | 41.0 | 2 | 0 |
| Fish Physiology | 41.0 | 2 | 0 |
| Computer Vision, Graphics, and Image Processing | 41.0 | 2 | 0 |
| Network Security | 41.0 | 2 | 0 |
| Inorganic and Nuclear Chemistry Letters | 41.0 | 2 | 0 |
| Inorganica Chimica Acta Reviews | 41.0 | 2 | 0 |
| Information Storage and Retrieval | 41.0 | 2 | 0 |
| bidirectional encoder representations from transformers | 41.0 | 2 | 0 |
| Biometric Technology Today | 41.0 | 2 | 0 |
| Membrane Technology | 41.0 | 2 | 0 |
| Filtration Industry Analyst | 41.0 | 2 | 0 |
| Fuel Cells Bulletin | 41.0 | 2 | 0 |
| Journal of Patient Safety & Infection Control | 41.0 | 2 | 0 |
| Pump Industry Analyst | 41.0 | 2 | 0 |
| Space Research Today | 41.0 | 2 | 0 |
| World Pumps | 41.0 | 2 | 0 |
| Christopher R. Conley | 41.0 | 2 | 0 |
| Blastocyst culture and transfer in clinical-assisted reproduction | 40.0 | 0 | 4 |
| Blastocyst culture and transfer in clinical-assisted reproduction: a committee opinion | 40.0 | 0 | 4 |
| Blastocyst culture and transfer in clinical-assisted reproduction | 40.0 | 0 | 4 |
| Blastocyst culture and transfer in clinically assisted reproduction: a committee opinion | 40.0 | 0 | 4 |
| assisted reproductive technology | 34.5 | 0 | 3 |
| fertility clinic | 34.5 | 0 | 3 |
| The correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women | 34.5 | 0 | 3 |
| Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone | 34.5 | 0 | 3 |
| A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist survey | 34.5 | 0 | 3 |
| Age-Related Normogram for Ovarian Antral Follicle Count in Women with Polycystic Ovary Syndrome and Comparison with Age Matched Controls Using Magnetic Resonance Imaging | 34.5 | 0 | 3 |
| Comparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve | 34.5 | 0 | 3 |
| Preimplantation genetic testing: a Practice Committee opinion | 34.5 | 0 | 3 |
| Anti-mullerian hormone and antral follicle count as predictors of ovarian response in assisted reproduction | 34.5 | 0 | 3 |
| Assessment of ovarian reserve: Anti-Mullerian hormone versus follicle stimulating hormone | 34.5 | 0 | 3 |
| The correlation of the antral follicle count and Serum anti-mullerian hormone | 34.5 | 0 | 3 |
| Elective single-embryo transfer | 34.5 | 0 | 3 |
| Shifting Paradigms in Diminished Ovarian Reserve and Advanced Reproductive Age in Assisted Reproduction: Customization Instead of Conformity | 34.5 | 0 | 3 |
| Embryo transfer techniques: an American Society for Reproductive Medicine survey of current Society for Assisted Reproductive Technology practices | 34.5 | 0 | 3 |
| Low AMH levels as a marker of reduced ovarian reserve in young women affected by Down's syndrome. | 34.5 | 0 | 3 |
| Impact of single embryo transfer policy on perinatal outcomes in fresh and frozen cycles—analysis of the Japanese Assisted Reproduction Technology registry between 2007 and 2012 | 34.5 | 0 | 3 |
| Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization | 34.5 | 0 | 3 |
| Embryo transfer by reproductive endocrinology fellows vs attending physicians: are live birth rates comparable? | 34.5 | 0 | 3 |
| Serum level of anti-mullerian hormone in early follicular phase as a predictor of ovarian reserve and pregnancy outcome in assisted reproductive technology cycles | 34.5 | 0 | 3 |
| Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? | 34.5 | 0 | 3 |
| Effect of premature serum progesterone rise on embryo transfer outcomes and the role of blastocyst culture and transfer in assisted reproductive technology cycles with premature progesterone rise | 34.5 | 0 | 3 |
| Predicting ovarian reserve and reproductive outcome using antimüllerian hormone (AMH) and antral follicle count (AFC) in patients with previous assisted reproduction technique (ART) failure | 34.5 | 0 | 3 |
| Prediction of ovarian reserve based on day-3 serum follicle stimulating hormone concentrations during the pituitary suppression cycle using a gonadotropin releasing hormone agonist in patients undergoing in vitro fertilization-embryo transfer | 34.5 | 0 | 3 |
| Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle | 34.5 | 0 | 3 |
| A cost-effectiveness analysis of preimplantation genetic testing for aneuploidy (PGT-A) for up to three complete assisted reproductive technology cycles in women of advanced maternal age | 34.5 | 0 | 3 |
| Laparoscopic Ovarian Cystectomy of Endometrioma vs Deroofing and Ovarian Reserve | 34.5 | 0 | 3 |
| Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study | 34.5 | 0 | 3 |
| Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients | 34.5 | 0 | 3 |
| Assessment of United States fertility clinic websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines | 34.5 | 0 | 3 |
| Pregnancy outcome following in vitro fertilization-embryo transfer (IVF-ET) in women of more advanced reproductive age with elevated serum follicle stimulating hormone (FSH) levels | 34.5 | 0 | 3 |
| Preimplantation genetic testing: a Practice Committee opinion | 34.5 | 0 | 3 |
| Prediction of ovarian reserve, poor response and pregnancy outcome based on basal antral follicle count and age in patients undergoing in vitro fertilization-embryo transfer | 34.5 | 0 | 3 |
| Role of baseline antral follicle count and anti-Mullerian hormone in the index stimulation cycle of IVF treatment in predicting outcome of subsequent frozen-thawed embryo transfers | 34.5 | 0 | 3 |
| The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion | 34.5 | 0 | 3 |
| Can delivery mode influence future ovarian reserve? Anti-Mullerian hormone levels and antral follicle count following cesarean section: a prospective cohort study | 34.5 | 0 | 3 |
| A 5-year analysis of demographics, cycle characteristics and reproductive outcomes of 907 egg freezing cycles in patients with diminished ovarian reserve and age-related fertility decline | 34.5 | 0 | 3 |
| Does embryo biopsy, independent of vitrification, impact perinatal outcomes? An analysis of perinatal outcomes following preimplantation genetic testing biopsy in fresh and frozen embryo transfer cycles | 34.5 | 0 | 3 |
| Anti-mullerian hormone level as a predictor of ovarian reserve in patients seeking fertility preservation versus infertility treatment | 34.5 | 0 | 3 |
| Embryo biopsy does not affect the rate of multiples after single embryo transfer (SET): a review of the society for assisted reproductive technology (SART) reported outcomes | 34.5 | 0 | 3 |
| Antral Follicle Count versus Basal Follicle Stimulating Hormone as Predictors of Ovarian Response in Women Undergoing Superovulation with Long Protocol for Assisted Reproduction | 34.5 | 0 | 3 |
| GYN-FIV a.s. | 34.5 | 0 | 3 |
| egg donation | 27.3 | 0 | 2 |
| Journal of Assisted Reproduction and Genetics | 27.3 | 0 | 2 |
| Reproductive Medicine and Biology | 27.3 | 0 | 2 |
| Application of seminal plasma to female genital tract prior to embryo transfer in assisted reproductive technology cycles (IVF, ICSI and frozen embryo transfer) | 27.3 | 0 | 2 |
| Post-embryo transfer interventions for assisted reproduction technology cycles | 27.3 | 0 | 2 |
| Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology | 27.3 | 0 | 2 |
| Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology | 27.3 | 0 | 2 |
| Soft versus firm embryo transfer catheters for assisted reproductive technology | 27.3 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles | 27.3 | 0 | 2 |
| Journal of Experimental & Clinical Assisted Reproduction: shaping the future of research and practice in reproductive endocrinology/infertility | 27.3 | 0 | 2 |
| Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology | 27.3 | 0 | 2 |
| A Review of The Society for Assisted Reproductive Technology Embryo Grading System and Proposed Modification | 27.3 | 0 | 2 |
| Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers | 27.3 | 0 | 2 |
| <i>In vitro</i> fertilization in Japan — Early days of <i>in vitro</i> fertilization and embryo transfer and future prospects for assisted reproductive technology — | 27.3 | 0 | 2 |
| Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents | 27.3 | 0 | 2 |
| What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation? | 27.3 | 0 | 2 |
| Impact of men's dairy intake on assisted reproductive technology outcomes among couples attending a fertility clinic | 27.3 | 0 | 2 |
| Urinary phthalate metabolites and ovarian reserve among women seeking infertility care | 27.3 | 0 | 2 |
| Which cut-off value of serum anti-Müllerian hormone level can predict poor ovarian reserve, poor ovarian response to stimulation andin vitrofertilization success? A prospective data analysis | 27.3 | 0 | 2 |
| Risk of major congenital anomalies after assisted hatching: analysis of three-year data from the national assisted reproduction registry in Japan | 27.3 | 0 | 2 |
| The role of assisted hatching in in vitro fertilization: a review of the literature. A committee opinion | 27.3 | 0 | 2 |
| Pregnancy outcomes after assisted reproductive technology | 27.3 | 0 | 2 |
| Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: the International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review of ovarian reserve test accuracy | 27.3 | 0 | 2 |
| Chromosomal abnormalities in miscarriages after different assisted reproduction procedures. | 27.3 | 0 | 2 |
| Fertility clinic, egg donation agency, and sperm bank policies | 27.3 | 0 | 2 |
| The status of assisted reproductive technology in Korea in 2012 | 27.3 | 0 | 2 |
| Live birth in a 46 year old using autologous oocytes cryopreserved for a duration of 3 years: a case report documenting fertility preservation at an advanced reproductive age | 27.3 | 0 | 2 |
| A successful pregnancy following 'double rescue' egg retrieval in a woman with Natural cycle IVF | 27.3 | 0 | 2 |
| The incidence of monozygotic twinning in assisted reproductive technology: Analysis based on results from the 2010 Japanese ART national registry | 27.3 | 0 | 2 |
| Antral follicle count in normal (fertility-proven) and infertile Indian women | 27.3 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. | 27.3 | 0 | 2 |
| RETIRED: Advanced Reproductive Age and Fertility | 27.3 | 0 | 2 |
| How the FMR1 gene became relevant to female fertility and reproductive medicine | 27.3 | 0 | 2 |
| Age = egg quality, FSH level = egg quantity | 27.3 | 0 | 2 |
| Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH | 27.3 | 0 | 2 |
| Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011. | 27.3 | 0 | 2 |
| Is tubal embryo transfer of any value? A meta-analysis and comparison with the Society for Assisted Reproductive Technology database | 27.3 | 0 | 2 |
| Ovarian response and cumulative live birth rate of women undergoing in-vitro fertilisation who had discordant anti-Mullerian hormone and antral follicle count measurements: a retrospective study. | 27.3 | 0 | 2 |
| Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial. | 27.3 | 0 | 2 |
| Fetal nuchal translucency scan and early prenatal diagnosis of chromosomal abnormalities by rapid aneuploidy screening: observational study | 27.3 | 0 | 2 |
| Factors influencing pregnancy rates with a combined clomiphene citrate/gonadotropin protocol for non-assisted reproductive technology fertility treatment | 27.3 | 0 | 2 |
| Anti-Mullerian Hormone: A Marker of Ovarian Reserve and its Association with Polycystic Ovarian Syndrome | 27.3 | 0 | 2 |
| Testing for Ovarian Reserve in Assisted Reproduction programs: the current point of view | 27.3 | 0 | 2 |
| The impact of endometrioma and laparoscopic cystectomy on ovarian reserve and the exploration of related factors assessed by serum anti-Mullerian hormone: a prospective cohort study | 27.3 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons: a committee opinion | 27.3 | 0 | 2 |
| Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis. | 27.3 | 0 | 2 |
| Risk of breast cancer following fertility treatment—A registry based cohort study of parous women in Norway | 27.3 | 0 | 2 |
| Chronological age vs biological age: an age-related normogram for antral follicle count, FSH and anti-Mullerian hormone. | 27.3 | 0 | 2 |
| A healthy delivery of twins by assisted reproduction followed by preimplantation genetic screening in a woman with X-linked dominant incontinentia pigmenti | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile | 27.3 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons | 27.3 | 0 | 2 |
| Risk of Chromosomal Abnormalities in Early Spontaneous Abortion after Assisted Reproductive Technology: A Meta-Analysis | 27.3 | 0 | 2 |
| Ongoing Pregnancy Rates in Women with Low and Extremely Low AMH Levels. A Multivariate Analysis of 769 Cycles | 27.3 | 0 | 2 |
| Evidence to Incorporate Inclusive Reproductive Health Measures in Guidelines for Childhood and Adolescent Cancer Survivors | 27.3 | 0 | 2 |
| Age-specific serum anti-mullerian hormone and follicle stimulating hormone concentrations in infertile Iranian women | 27.3 | 0 | 2 |
| A legal-ethical analysis of reproductive endocrinologists' right to refuse ovulation induction to patients with diminished ovarian reserve | 27.3 | 0 | 2 |
| The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility | 27.3 | 0 | 2 |
| Optimal timing for elective egg freezing | 27.3 | 0 | 2 |
| What is the most relevant standard of success in assisted reproduction?: challenges in measuring and reporting success rates for assisted reproductive technology treatments: what is optimal? | 27.3 | 0 | 2 |
| Predictive value of age-specific FSH levels for IVF-ET outcome in women with normal ovarian function | 27.3 | 0 | 2 |
| Oocyte retrieval at 140-mmHg negative aspiration pressure: A promising alternative to flushing and aspiration in assisted reproduction in women with low ovarian reserve | 27.3 | 0 | 2 |
| What is the most relevant standard of success in assisted reproduction? Redefining success in the context of elective single embryo transfer: evidence, intuition and financial reality | 27.3 | 0 | 2 |
| Antiphospholipid antibodies do not affect IVF success | 27.3 | 0 | 2 |
| Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes | 27.3 | 0 | 2 |
| Reduction of multiple pregnancies in the advanced maternal age population after implementation of an elective single embryo transfer policy coupled with enhanced embryo selection: pre- and post-intervention study | 27.3 | 0 | 2 |
| Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation | 27.3 | 0 | 2 |
| Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System | 27.3 | 0 | 2 |
| Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunity | 27.3 | 0 | 2 |
| Serum anti-müllerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles. | 27.3 | 0 | 2 |
| Embryo transfer practices and multiple births resulting from assisted reproductive technology: an opportunity for prevention | 27.3 | 0 | 2 |
| Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide | 27.3 | 0 | 2 |
| Measurement of antral follicle count in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey | 27.3 | 0 | 2 |
| Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis | 27.3 | 0 | 2 |
| The practical implications of a raised serum FSH and age on the risk of IVF treatment cancellation due to a poor ovarian response | 27.3 | 0 | 2 |
| Comparison of basal and clomiphene citrate induced FSH and inhibin B, ovarian volume and antral follicle counts as ovarian reserve tests and predictors of poor ovarian response in IVF. | 27.3 | 0 | 2 |
| A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment | 27.3 | 0 | 2 |
| Elective single-embryo transfer improves cumulative pregnancy outcome in young patients but not in women of advanced reproductive age | 27.3 | 0 | 2 |
| Day 3 embryo transfer may have better pregnancy outcomes in younger than 35-year-old patients with poor ovarian response | 27.3 | 0 | 2 |
| Anti-mullerian hormone cut-off values for predicting poor ovarian response to exogenous ovarian stimulation in in-vitro fertilization | 27.3 | 0 | 2 |
| Firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis using direct and adjusted indirect comparisons | 27.3 | 0 | 2 |
| Oncofertility: a grand collaboration between reproductive medicine and oncology | 27.3 | 0 | 2 |
| Embryo transfer in days 2 to 4 following intracytoplasmic sperm injection: a prospective cohort study | 27.3 | 0 | 2 |
| Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates | 27.3 | 0 | 2 |
| Genetic considerations related to intracytoplasmic sperm injection (ICSI). | 27.3 | 0 | 2 |
| Guidelines for reducing the risk of viral transmission during fertility treatment | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI). | 27.3 | 0 | 2 |
| Anti-phospholipid antibodies do not affect IVF success | 27.3 | 0 | 2 |
| Single thawed euploid embryo transfer improves IVF pregnancy, miscarriage, and multiple gestation outcomes and has similar implantation rates as egg donation. | 27.3 | 0 | 2 |
| The role of fertility preservation in patients with endometriosis | 27.3 | 0 | 2 |
| Treatment strategies in assisted reproduction for women of advanced maternal age. | 27.3 | 0 | 2 |
| Current status of assisted reproductive technology in Korea, 2011 | 27.3 | 0 | 2 |
| On the Morphology of the Human Sertoli Cells under Normal Conditions and in Patients with Impaired Fertility* | 27.3 | 0 | 2 |
| Antral follicle count determines poor ovarian response better than anti-müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles | 27.3 | 0 | 2 |
| The predictive value of anti-Mullerian hormone on embryo quality, blastocyst development, and pregnancy rate following in vitro fertilization-embryo transfer (IVF-ET). | 27.3 | 0 | 2 |
| Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies | 27.3 | 0 | 2 |
| Use of letrozole in assisted reproduction: a systematic review and meta-analysis. | 27.3 | 0 | 2 |
| Post-thaw Embryo Transfer Cycles as the Future Hope for Boosting IVF Success Rates | 27.3 | 0 | 2 |
| Maternal age-specific rates of fetal chromosomal abnormalities in Korean pregnant women of advanced maternal age | 27.3 | 0 | 2 |
| The importance of rapid aneuploidy screening and prenatal diagnosis in the detection of numerical chromosomal abnormalities | 27.3 | 0 | 2 |
| Determining an anti-mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve | 27.3 | 0 | 2 |
| Assisted reproduction and fertility preservation techniques in cancer patients | 27.3 | 0 | 2 |
| Optimizing natural fertility | 27.3 | 0 | 2 |
| Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles | 27.3 | 0 | 2 |
| Anti-Müllerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies | 27.3 | 0 | 2 |
| Assisted reproductive technology use, embryo transfer practices, and birth outcomes after infertility insurance mandates: New Jersey and Connecticut | 27.3 | 0 | 2 |
| Discrepancies between Antimullerian Hormone and Follicle Stimulating Hormone in Assisted Reproduction | 27.3 | 0 | 2 |
| Costs of achieving live birth from assisted reproductive technology: a comparison of sequential single and double embryo transfer approaches | 27.3 | 0 | 2 |
| Age-specific nomograms for follicle stimulating hormone and anti-Mullerian hormone: A pilot study in Ile-Ife, Nigeria | 27.3 | 0 | 2 |
| Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). | 27.3 | 0 | 2 |
| Anti-mullerian hormone as a predictor of ovarian reserve and ovarian response in IVF women from Gaza strip | 27.3 | 0 | 2 |
| Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location | 27.3 | 0 | 2 |
| Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms | 27.3 | 0 | 2 |
| Limb-body wall complex in one fetus of a dizygotic twin pregnancy conceived by egg donation, in vitro fertilization and embryo transfer: prenatal diagnosis and literature review | 27.3 | 0 | 2 |
| Anti-Mullerian Hormone: A New Marker of Ovarian Function | 27.3 | 0 | 2 |
| Prevalence of chromosomal abnormalities and timing of karyotype analysis in patients with recurrent implantation failure (RIF) following assisted reproduction | 27.3 | 0 | 2 |
| Human blastocyst culture in IVF: current laboratory applications in reproductive medicine practice | 27.3 | 0 | 2 |
| The promise of in vitro maturation in assisted reproduction and fertility preservation. | 27.3 | 0 | 2 |
| What is the role of assisted reproduction technology in the management of age-related infertility? | 27.3 | 0 | 2 |
| Pregnancy rates following frozen embryo transfer (ET) in women failing to conceive despite fresh ET in women using low dosage follicle stimulating hormone (FSH) protocol for follicular maturation of several eggs | 27.3 | 0 | 2 |
| Intracytoplasmic sperm injection (ICSI) for non-male factor infertility: a committee opinion | 27.3 | 0 | 2 |
| In vitro maturation: a committee opinion | 27.3 | 0 | 2 |
| Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? | 27.3 | 0 | 2 |
| Comprehensive chromosome screening of trophectoderm with vitrification facilitates elective single-embryo transfer for infertile women with advanced maternal age. | 27.3 | 0 | 2 |
| The wobbly evidence base of reproductive medicine | 27.3 | 0 | 2 |
| Freezing the biological clock: a viable fertility preservation option for young Singapore women? | 27.3 | 0 | 2 |
| Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients | 27.3 | 0 | 2 |
| Misconduct in third-party assisted reproduction: a committee opinion | 27.3 | 0 | 2 |
| VACTERL association with hydrocephalus in a fetus conceived by in vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Female age-related fertility decline. Committee Opinion No. 589. | 27.3 | 0 | 2 |
| Cryopreservation and delayed embryo transfer-assisted reproductive technology registry and reporting implications | 27.3 | 0 | 2 |
| Role of assisted hatching in in vitro fertilization: a guideline | 27.3 | 0 | 2 |
| Recommended practices for the management of embryology, andrology, and endocrinology laboratories: a committee opinion | 27.3 | 0 | 2 |
| The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis. | 27.3 | 0 | 2 |
| AMH: An ovarian reserve biomarker in assisted reproduction. | 27.3 | 0 | 2 |
| Assisted reproductive technology - IVF treatment in Ireland: A study of couples with successful outcomes | 27.3 | 0 | 2 |
| Does weight loss in overweight or obese women improve fertility treatment outcomes? A systematic review | 27.3 | 0 | 2 |
| Fertility preservation for age-related fertility decline | 27.3 | 0 | 2 |
| Methods employed to overcome difficult embryo transfer during assisted reproduction treatment | 27.3 | 0 | 2 |
| Role of tubal surgery in the era of assisted reproductive technology: a committee opinion | 27.3 | 0 | 2 |
| The clinical efficacy and efficiency of a 100-IU starting dose of recombinant follicle stimulating hormone (Puregon) in Korean women undergoing in vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Role of the mental health professional in education and support of the medical staff | 27.3 | 0 | 2 |
| Subclinical hypothyroidism in the infertile female population: a guideline | 27.3 | 0 | 2 |
| Fertility Preservation in Women with Ovarian Endometriosis | 27.3 | 0 | 2 |
| Molecular aspects and clinical methods for preserving ovarian reserves in women receiving cancer treatment | 27.3 | 0 | 2 |
| What women want? A scoping survey on women's knowledge, attitudes and behaviours towards ovarian reserve testing and egg freezing. | 27.3 | 0 | 2 |
| Effect of advanced maternal age on maternal and neonatal outcomes in assisted reproductive technology pregnancies | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Long-acting follicle-stimulating hormone versus daily follicle-stimulating hormone for women undergoing assisted reproduction | 27.3 | 0 | 2 |
| Urinary triclosan concentrations and diminished ovarian reserve among women undergoing treatment in a fertility clinic | 27.3 | 0 | 2 |
| The effect of peri-implantation administration of uterine relaxing agents in assisted reproduction treatment cycles: a systematic review and meta-analysis | 27.3 | 0 | 2 |
| Infertility in advanced reproductive age. Results of in vitro fertilization and embryo transfer according to the woman's age. | 27.3 | 0 | 2 |
| Maternal Racial and Ethnic Disparities in Neonatal Birth Outcomes With and Without Assisted Reproduction | 27.3 | 0 | 2 |
| Assessment of ovarian reserve and fertility preservation strategies in children treated for cancer. | 27.3 | 0 | 2 |
| Increasing awareness of age-related fertility and elective fertility preservation among medical students and house staff: a pre- and post-intervention analysis | 27.3 | 0 | 2 |
| Factors predicting double embryo implantation following double embryo transfer in assisted reproductive technology: implications for elective single embryo transfer | 27.3 | 0 | 2 |
| EXPRESSION OF CONCERN: Addition of growth hormone to the microflare stimulation protocol among women with poor ovarian response | 27.3 | 0 | 2 |
| Guidance on the limits to the number of embryos to transfer: a committee opinion | 27.3 | 0 | 2 |
| Perinatal outcomes among singletons after assisted reproductive technology with single-embryo or double-embryo transfer versus no assisted reproductive technology | 27.3 | 0 | 2 |
| Embryo transfer simulation improves pregnancy rates and decreases time to proficiency in Reproductive Endocrinology and Infertility fellow embryo transfers | 27.3 | 0 | 2 |
| The cutoff values of serum AMH levels and starting recFSH doses for the individualization of IVF treatment strategies | 27.3 | 0 | 2 |
| Practice patterns, satisfaction, and demographics of reproductive endocrinologists: results of the 2014 Society for Reproductive Endocrinology and Infertility Workforce Survey | 27.3 | 0 | 2 |
| Omics in Reproductive Medicine: Application of Novel Technologies to Improve the IVF Success Rate | 27.3 | 0 | 2 |
| Pregnancy After Modified Natural Cycle IVF: Case Report of a Young Patient With Elevated FSH Levels and Male Factor Infertility | 27.3 | 0 | 2 |
| Performing the embryo transfer: a guideline | 27.3 | 0 | 2 |
| Effect of smoking on ovarian reserve and ovarian stimulation in in- vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion | 27.3 | 0 | 2 |
| Comparison of serum anti-mullerian hormone among fertile and infertile normal and diminished ovarian reserve groups | 27.3 | 0 | 2 |
| Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria | 27.3 | 0 | 2 |
| A multicenter study of fetal chromosomal abnormalities in Chinese women of advanced maternal age. | 27.3 | 0 | 2 |
| Assisted reproductive technology: public funding and the voluntary shift to single embryo transfer in Australia | 27.3 | 0 | 2 |
| The fertility myth: Israeli students' knowledge regarding age-related fertility decline and late pregnancies in an era of assisted reproduction technology. | 27.3 | 0 | 2 |
| Egg freezing for age-related fertility decline: preventive medicine or a further medicalization of reproduction? Analyzing the new Israeli policy | 27.3 | 0 | 2 |
| Assisted reproductive techniques in Latin America: the Latin American Registry, 2013 | 27.3 | 0 | 2 |
| Assisted reproductive medicine in Poland --Fertility and Sterility Special Interest Group of the Polish Gynaecological Society (SPiN PTG) 2012 report | 27.3 | 0 | 2 |
| Pain during embryo transfer is independently associated with clinical pregnancy in fresh/frozen assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Position statement on West Nile virus: a committee opinion | 27.3 | 0 | 2 |
| Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years | 27.3 | 0 | 2 |
| Assisted reproduction policies in Israel: a retrospective analysis of in vitro fertilization–embryo transfer | 27.3 | 0 | 2 |
| Assessment of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with familial Mediterranean fever | 27.3 | 0 | 2 |
| Women's intentions to use fertility preservation to prevent age-related fertility decline | 27.3 | 0 | 2 |
| Higher proportion of birth defects with assisted reproductive technology may not be attributable to advanced maternal age. | 27.3 | 0 | 2 |
| Specific ranges of anti-Mullerian hormone and antral follicle count correlate to provide a prognostic indicator for IVF outcome | 27.3 | 0 | 2 |
| Recommendations for practices utilizing gestational carriers: a committee opinion | 27.3 | 0 | 2 |
| Is there an effect of thyroid autoimmunity on the outcomes of assisted reproduction? | 27.3 | 0 | 2 |
| American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile virus | 27.3 | 0 | 2 |
| Fertility preservation and reproduction in cancer patients | 27.3 | 0 | 2 |
| Predictive values of anti-müllerian hormone, antral follicle count and ovarian response prediction index (ORPI) for assisted reproductive technology outcomes | 27.3 | 0 | 2 |
| American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile virus | 27.3 | 0 | 2 |
| Risk of ectopic pregnancy is linked to endometrial thickness in a retrospective cohort study of 8120 assisted reproduction technology cycles | 27.3 | 0 | 2 |
| American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile Virus | 27.3 | 0 | 2 |
| Cumulative number and morphological score of embryos resulting in success: realistic expectations from in vitro fertilization-embryo transfer | 27.3 | 0 | 2 |
| Physical health of singleton children born after frozen embryo transfer using slow freezing: a 3-year follow-up study | 27.3 | 0 | 2 |
| The relationship between the changes in the level of progesterone and the outcome ofin vitrofertilization-embryo transfer | 27.3 | 0 | 2 |
| Comparing four ovarian reserve markers--associations with ovarian response and live births after assisted reproduction | 27.3 | 0 | 2 |
| Position on reproductive donors and smallpox vaccine: a committee opinion | 27.3 | 0 | 2 |
| Hormonal and Clinical Predictors for Post-egg Retrieval Pain in Women Undergoing Assisted Reproductive Technology Procedures. | 27.3 | 0 | 2 |
| Current differences and consequences of legislation on practice of assisted reproductive technology in the Nordic countries. The Nordic Committee on Assisted Reproduction of the Scandinavian Federation of Societies of Obstetrics and Gynecology | 27.3 | 0 | 2 |
| Effect of Methotrexate or Salpingectomy for Ectopic Pregnancy on Subsequent In Vitro Fertilization–Embryo Transfer Outcomes | 27.3 | 0 | 2 |
| Safety in reproductive medicine: breadth, depth and discovery | 27.3 | 0 | 2 |
| Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies | 27.3 | 0 | 2 |
| Advanced maternal age: ethical and medical considerations for assisted reproductive technology | 27.3 | 0 | 2 |
| Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials | 27.3 | 0 | 2 |
| Testing and interpreting measures of ovarian reserve: a committee opinion | 27.3 | 0 | 2 |
| The Russian experience of autotransplantation of vitrified ovarian tissue to a cancer patient | 27.3 | 0 | 2 |
| Mature oocyte cryopreservation: a guideline | 27.3 | 0 | 2 |
| Lapse in embryo transfer training does not negatively affect clinical pregnancy rates for reproductive endocrinology and infertility fellows | 27.3 | 0 | 2 |
| Pregnancy outcomes in very advanced maternal age pregnancies: the impact of assisted reproductive technology | 27.3 | 0 | 2 |
| Recommendations for development of an emergency plan for in vitro fertilization programs: a committee opinion | 27.3 | 0 | 2 |
| Recommendations for development of an emergency plan for in vitro fertilization programs: a committee opinion | 27.3 | 0 | 2 |
| Guidelines for development of an emergency plan for in vitro fertilization programs | 27.3 | 0 | 2 |
| Tiaogeng Yijing decoction improves the pregnancy outcomes of patients with poor ovarian response undergoing in vitro fertilization-embryo transfer | 27.3 | 0 | 2 |
| Fertility Treatments in the United States: Improving Access and Outcomes | 27.3 | 0 | 2 |
| Viability of cumulus cells is associated with basal AMH levels in assisted reproduction. | 27.3 | 0 | 2 |
| Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated with gonadotropin after pituitary suppression | 27.3 | 0 | 2 |
| Age-specific FSH levels as a tool for appropriate patient counselling in assisted reproduction | 27.3 | 0 | 2 |
| Prospective evaluation of basal stromal Doppler studies in women with good ovarian reserve and infertility undergoing in vitro fertilization-embryo transfer treatment: patients with polycystic ovary syndrome versus ovulatory patients. | 27.3 | 0 | 2 |
| Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women | 27.3 | 0 | 2 |
| Biological versus chronological ageing of oocytes, distinguishable by raised FSH levels in relation to the success of IVF treatment | 27.3 | 0 | 2 |
| IVF Treatment and Single Embryo Transfer | 27.3 | 0 | 2 |
| Serum anti-Mullerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy | 27.3 | 0 | 2 |
| Clinical Utility of Measurement of Anti-Müllerian Hormone in Reproductive Endocrinology | 27.3 | 0 | 2 |
| Do ovarian reserve tests predict miscarriage in women undergoing assisted reproduction treatment? | 27.3 | 0 | 2 |
| Effects of electroacupuncture on in vitro fertilization-embryo transfer (IVF-ET) of patients with poor ovarian response | 27.3 | 0 | 2 |
| Refuting a misguided campaign against the goal of single-embryo transfer and singleton birth in assisted reproduction | 27.3 | 0 | 2 |
| Repetitive oocyte donation: a committee opinion | 27.3 | 0 | 2 |
| Cystic fibrosis (cf) and ovarian reserve: A cross-sectional study examining serum anti-mullerian hormone (amh) in young women | 27.3 | 0 | 2 |
| Triple marker screening for fetal chromosomal abnormalities in Korean women of advanced maternal age. | 27.3 | 0 | 2 |
| Optimizing natural fertility: a committee opinion | 27.3 | 0 | 2 |
| Life after unsuccessful IVF treatment in an assisted reproduction unit: a qualitative analysis of gains through loss among Chinese persons in Hong Kong. | 27.3 | 0 | 2 |
| Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist | 27.3 | 0 | 2 |
| Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion | 27.3 | 0 | 2 |
| Estimation of the Contribution of Assisted and Non-Assisted Reproductive Technology Fertility Treatments to Multiple Births During the Past 30 Years in Japan: 1979–2008 | 27.3 | 0 | 2 |
| Perinatal outcomes after assisted reproductive technology treatment in Australia and New Zealand: single versus double embryo transfer. | 27.3 | 0 | 2 |
| Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve | 27.3 | 0 | 2 |
| Examining the relationship between ovarian reserve, as measured by basal FSH levels, and the risk of poor obstetric outcome in singleton IVF gestations | 27.3 | 0 | 2 |
| The serum concentration of estradiol after embryo transfer and the decline from preovulatory levels may influence the success of IVF treatment | 27.3 | 0 | 2 |
| Egg donation in an in vitro fertilization program: an alternative approach to cycle synchronization and timing of embryo transfer | 27.3 | 0 | 2 |
| Pure human follicle stimulating hormone has a role in the treatment of severe male infertility by assisted reproduction: Norfolk's total experience | 27.3 | 0 | 2 |
| Ovarian stimulation for in vitro fertilization and embryo transfer, human menopausal gonadotropin versus pure human follicle stimulating hormone: a randomized prospective study. | 27.3 | 0 | 2 |
| Spontaneous luteinizing hormone (LH) surges are associated with more rapidly increasing estradiol (E2) and follicle stimulating hormone (FSH) in in vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Perspective on in vitro fertilization and embryo transfer. Stimulus for biomedical research in reproductive medicine | 27.3 | 0 | 2 |
| Evidence-based medicine and the role of the private sector in assisted reproduction: a response to Dr Fishel’s commentary ‘Evidenced-based medicine and the role of the National Health Service in assisted reproduction’ | 27.3 | 0 | 2 |
| Risk-sharing or refund programs in assisted reproduction: a committee opinion | 27.3 | 0 | 2 |
| Reproductive medicine and the law: egg donation in Germany, Spain and other European countries | 27.3 | 0 | 2 |
| Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial | 27.3 | 0 | 2 |
| Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment | 27.3 | 0 | 2 |
| Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level | 27.3 | 0 | 2 |
| Anti-mullerian hormone as a marker of ovarian reserve | 27.3 | 0 | 2 |
| Antral follicle count and FSH concentration after clomiphene citrate challenge test in the prediction of ovarian response during IVF treatment | 27.3 | 0 | 2 |
| Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial | 27.3 | 0 | 2 |
| First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient | 27.3 | 0 | 2 |
| The association between poor ovarian response and thrombophilia in assisted reproduction | 27.3 | 0 | 2 |
| Society for Assisted Reproductive Technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Society for Assisted Reproductive Technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Society for assisted reproductive technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Society for assisted reproductive technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Obstetrical and neonatal outcomes from the BEST Trial: single embryo transfer with aneuploidy screening improves outcomes after in vitro fertilization without compromising delivery rates | 27.3 | 0 | 2 |
| Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation | 27.3 | 0 | 2 |
| Anti-Mullerian hormone (AMH): what do we still need to know? | 27.3 | 0 | 2 |
| The Impact of Adnexal Torsion on Antral Follicle Count when Compared With Contralateral Ovary | 27.3 | 0 | 2 |
| Guidelines on number of embryos transferred | 27.3 | 0 | 2 |
| Blastocyst culture is associated with an elevated incidence of monozygotic twinning after single embryo transfer | 27.3 | 0 | 2 |
| Public policy aspects of assisted reproduction. Vth World Congress, IVF and embryo transfer | 27.3 | 0 | 2 |
| Fertility preservation for men with testicular cancer: Is sperm cryopreservation cost effective in the era of assisted reproductive technology? | 27.3 | 0 | 2 |
| Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure | 27.3 | 0 | 2 |
| Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin | 27.3 | 0 | 2 |
| Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Repo | 27.3 | 0 | 2 |
| The three-dimensional ultrasonographic ovarian vascularity of women developing poor ovarian response during assisted reproduction treatment and its predictive value | 27.3 | 0 | 2 |
| Trends and factors associated with the Day 5 embryo transfer, assisted reproductive technology surveillance, USA, 2001-2009. | 27.3 | 0 | 2 |
| Antral follicle count at down-regulation and prediction of poor ovarian response | 27.3 | 0 | 2 |
| Does very advanced maternal age, with or without egg donation, really increase obstetric risk in a large tertiary center? | 27.3 | 0 | 2 |
| Infertile women of advanced reproductive age. Variability of day 3 FSH and E2 levels. | 27.3 | 0 | 2 |
| Evolution of a reproductive endocrinologist: the Society for Reproductive Endocrinology and Infertility fellows retreat and preliminary results of manpower survey | 27.3 | 0 | 2 |
| Embryo transfer practices in the United States: a survey of clinics registered with the Society for Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Posthumous assisted reproduction: a survey of attitudes of couples seeking fertility treatment and the degree of agreement between intimate partners | 27.3 | 0 | 2 |
| Viral infections among couples for assisted reproduction in a fertility clinic in Nigeria. | 27.3 | 0 | 2 |
| Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program | 27.3 | 0 | 2 |
| Factors associated with dizygotic twinning after IVF treatment with double embryo transfer | 27.3 | 0 | 2 |
| Treatment period and medical care costs to achieve the first live birth by assisted reproductive technology are lower in the single embryo transfer period than in the double embryo transfer period: a retrospective analysis of women younger than 40 y | 27.3 | 0 | 2 |
| Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome | 27.3 | 0 | 2 |
| No increase in autism-associated genetic events in children conceived by assisted reproduction | 27.3 | 0 | 2 |
| Three successful pregnancies with in vitro fertilization embryo transfer over an eight year time span despite elevated basal serum follicle stimulating hormone levels. Case report | 27.3 | 0 | 2 |
| Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion | 27.3 | 0 | 2 |
| Age-related nomograms for antral follicle count and anti-Mullerian hormone for subfertile Chinese women in Singapore | 27.3 | 0 | 2 |
| Not all twins are monozygotic after elective single embryo transfer: analysis of 32,600 elective single embryo transfer cycles as reported to the Society for Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Medical egg freezing: the importance of a patient-centered approach to fertility preservation | 27.3 | 0 | 2 |
| Medical egg freezing and cancer patients' hopes: Fertility preservation at the intersection of life and death | 27.3 | 0 | 2 |
| Stimulation of endometrium embryo transfer can improve implantation and pregnancy rates for patients undergoing assisted reproductive technology for the first time with a high-grade blastocyst | 27.3 | 0 | 2 |
| Congenital Malformations in Singleton Infants Conceived by Assisted Reproductive Technologies and Singleton Infants by Natural Conception in Tehran, Iran | 27.3 | 0 | 2 |
| Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss in younger in vitro fertilization patients | 27.3 | 0 | 2 |
| Egg Freezing for Age-Related Fertility Decline | 27.3 | 0 | 2 |
| The Impact of a Long-Acting Oral Sphingosine-1-Phosphate Analogue on Ovarian Aging in a Rat Model | 27.3 | 0 | 2 |
| Effects of transcutaneous electrical acupoint stimulation on ovarian reserve of patients with diminished ovarian reserve in in vitro fertilization and embryo transfer cycles | 27.3 | 0 | 2 |
| The Importance of the Periconception Period: Immediate Effects in Cattle Breeding and in Assisted Reproduction Such as Artificial Insemination and Embryo Transfer | 27.3 | 0 | 2 |
| Provision of fertility services for women at increased risk of complications during fertility treatment or pregnancy: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Financial "risk-sharing" or refund programs in assisted reproduction: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Oocyte or embryo donation to women of advanced reproductive age: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Mitochondrial SIRT5 is present in follicular cells and is altered by reduced ovarian reserve and advanced maternal age | 27.3 | 0 | 2 |
| Correlation of serum anti-Mullerian hormone to follicular follicle stimulating hormone and implantation potential of the ensuing embryos | 27.3 | 0 | 2 |
| The impact of the new Turkish regulation, imposing single embryo transfer after assisted reproduction technology, on neonatal intensive care unit utilization: a single center experience. | 27.3 | 0 | 2 |
| Higher rates of aneuploidy in blastocysts and higher risk of no embryo transfer in recurrent pregnancy loss patients with diminished ovarian reserve undergoing in vitro fertilization | 27.3 | 0 | 2 |
| Donor Motivations, Associated Risks and Ethical Considerations of Oocyte Donation | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 2000 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1999 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1998 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Poor knowledge of age-related fertility decline and assisted reproduction among healthcare professionals | 27.3 | 0 | 2 |
| A Focus on Maternal Health Before Assisted Reproduction: Results From a Pilot Survey of Canadian IVF Medical Directors | 27.3 | 0 | 2 |
| Assisted reproductive technology in reproductive medicine - possibilities and limitations | 27.3 | 0 | 2 |
| Reproductive Ethics in Commercial Surrogacy: Decision-Making in IVF Clinics in New Delhi, India | 27.3 | 0 | 2 |
| The impact of unilateral oophorectomy on ovarian reserve in assisted reproduction: a systematic review and meta-analysis | 27.3 | 0 | 2 |
| Assessment of ovarian reserve by antral follicle count in ovaries with endometrioma | 27.3 | 0 | 2 |
| Predictive value of antral follicle count and serum anti-Müllerian hormone: Which is better for live birth prediction in patients aged over 40 with their first IVF treatment? | 27.3 | 0 | 2 |
| Melatonin concentration in follicular fluid is correlated with antral follicle count (AFC) and in vitro fertilization (IVF) outcomes in women undergoing assisted reproductive technology (ART) procedures. | 27.3 | 0 | 2 |
| Patient and cycle characteristics predicting high pregnancy rates with single-embryo transfer: an analysis of the Society for Assisted Reproductive Technology outcomes between 2004 and 2013. | 27.3 | 0 | 2 |
| Dehydroepiandrosterone supplementation in women undergoing assisted reproductive technology with poor ovarian response. A prospective case-control study | 27.3 | 0 | 2 |
| Effect of follicular flushing on reproductive outcomes in patients with poor ovarian response undergoing assisted reproductive technology | 27.3 | 0 | 2 |
| Initial maternal serum human chorionic gonadotropin levels in pregnancies achieved after assisted reproductive technology are higher after preimplantation genetic screening and after frozen embryo transfer: a retrospective cohort | 27.3 | 0 | 2 |
| Prediction value of anti-Mullerian hormone (AMH) serum levels and antral follicle count (AFC) in hormonal contraceptive (HC) users and non-HC users undergoing IVF-PGD treatment | 27.3 | 0 | 2 |
| There is no evidence that the time from egg retrieval to embryo transfer affects live birth rates in a freeze-all strategy | 27.3 | 0 | 2 |
| The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF. | 27.3 | 0 | 2 |
| American Society for Reproductive Medicine Updates Consent Forms for Egg Donation | 27.3 | 0 | 2 |
| Nondominant small follicles are a promising source of mature oocytes in modified natural cycle in vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Comparison between follicular stimulation and luteal stimulation protocols with clomiphene and HMG in women with poor ovarian response | 27.3 | 0 | 2 |
| BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles | 27.3 | 0 | 2 |
| Uncommon but devastating event: total fertilisation failure following intracytoplasmic sperm injection | 27.3 | 0 | 2 |
| Does ovarian reserve predict egg quality in unstimulated therapeutic donor insemination cycles? | 27.3 | 0 | 2 |
| The dynamic changes of anti-Mullerian hormone and inhibin B during controlled ovarian hyperstimulation in decreased ovarian reserve women and the effect on clinical outcome | 27.3 | 0 | 2 |
| Live birth in a 50-year-old woman following in vitro fertilization–embryo transfer with autologous oocytes: a rare case report | 27.3 | 0 | 2 |
| Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies: a committee opinion | 27.3 | 0 | 2 |
| Pregnancy rates in donor oocyte cycles compared to similar autologous in vitro fertilization cycles: an analysis of 26,457 fresh cycles from the Society for Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Mitochondrial SIRT3 and its target glutamate dehydrogenase are altered in follicular cells of women with reduced ovarian reserve or advanced maternal age | 27.3 | 0 | 2 |
| The impact of legally restricted embryo transfer and reimbursement policy on cumulative delivery rate after treatment with assisted reproduction technology | 27.3 | 0 | 2 |
| Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis | 27.3 | 0 | 2 |
| What is the quality of information on social oocyte cryopreservation provided by websites of Society for Assisted Reproductive Technology member fertility clinics? | 27.3 | 0 | 2 |
| Dehydroepiandrosterone supplementation improves predictive markers for diminished ovarian reserve: serum AMH, inhibin B and antral follicle count | 27.3 | 0 | 2 |
| A prediction model to select PCOS patients suitable for IVM treatment based on anti-Mullerian hormone and antral follicle count. | 27.3 | 0 | 2 |
| Recommendations for gamete and embryo donation: a committee opinion | 27.3 | 0 | 2 |
| Testing and interpreting measures of ovarian reserve: a committee opinion | 27.3 | 0 | 2 |
| Colour Doppler assessment of ascendent uterine artery perfusion in an in-vitro fertilization-embryo transfer programme after pituitary desensitization and ovarian stimulation with human recombinant follicle stimulating hormone | 27.3 | 0 | 2 |
| Women with reduced ovarian reserve or advanced maternal age have an altered follicular environment | 27.3 | 0 | 2 |
| Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve | 27.3 | 0 | 2 |
| The effect of laparoscopic ovarian cystectomy versus coagulation in bilateral endometriomas on ovarian reserve as determined by antral follicle count and ovarian volume: a prospective randomized study | 27.3 | 0 | 2 |
| Follicular-fluid anti-Mullerian hormone concentrations are predictive of assisted reproduction outcome in PCOS patients | 27.3 | 0 | 2 |
| Evaluation of compliance and range of fees among American Society for Reproductive Medicine-listed egg donor and surrogacy agencies | 27.3 | 0 | 2 |
| 2008 Guidelines for gamete and embryo donation: a Practice Committee report | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI). | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies | 27.3 | 0 | 2 |
| Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion | 27.3 | 0 | 2 |
| Improved pregnancy outcome for women with decreased ovarian oocyte reserve and advanced reproductive age by performing in vitro fertilization-embryo transfer | 27.3 | 0 | 2 |
| Guidelines for development of an emergency plan for in vitro fertilization programs | 27.3 | 0 | 2 |
| Does 3D ultrasound offer any advantage in the pretreatment assessment of ovarian reserve and prediction of outcome after assisted reproduction treatment? | 27.3 | 0 | 2 |
| Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation | 27.3 | 0 | 2 |
| Estimation of the contribution of non-assisted reproductive technology ovulation stimulation fertility treatments to US singleton and multiple births | 27.3 | 0 | 2 |
| Prognosis following in vitro fertilization-embryo transfer (IVF-ET) in patients with elevated day 2 or 3 serum follicle stimulating hormone (FSH) is better in younger vs older patients | 27.3 | 0 | 2 |
| Follicle stimulating hormone measured in unextracted urine throughout the menstrual cycle correlates with age and ovarian reserve | 27.3 | 0 | 2 |
| Assisted reproduction technique outcomes for fresh versus deferred cryopreserved day-2 embryo transfer: a retrospective matched cohort study | 27.3 | 0 | 2 |
| Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme | 27.3 | 0 | 2 |
| Ethical issues of egg donation | 27.3 | 0 | 2 |
| Parameters that influence the results of in vitro fertilization/embryo transfer: a study of an egg donation model | 27.3 | 0 | 2 |
| Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F) in non-down-regulated cycles | 27.3 | 0 | 2 |
| Controversies in assisted reproduction: oocyte donation. Protocols for egg donation | 27.3 | 0 | 2 |
| Birthweight of singletons after assisted reproduction is higher after single- than after double-embryo transfer | 27.3 | 0 | 2 |
| Relationship between serum anti-Mullerian hormone and intrafollicular AMH levels in PCOS women | 27.3 | 0 | 2 |
| Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. | 27.3 | 0 | 2 |
| Single embryo implantation per IVF cycle: the answer to every request for assisted reproduction? | 27.3 | 0 | 2 |
| Assisted reproductive technology : strategies of elective single embryo transfer | 27.3 | 0 | 2 |
| Comparison of embryo transfer strategies and assisted reproduction outcome in Slovenian and cross-border patients | 27.3 | 0 | 2 |
| The significance of blastocyst culture for discarded embryos in the treatment period of in-vitro fertilization and embryo transfer without available embryos | 27.3 | 0 | 2 |
| CLINICAL ASSISTED REPRODUCTION: Comparison of Recombinant and Urinary Follicle-Stimulating Hormone Preparations in Short-Term Gonadotropin Releasing Hormone Agonist Protocol for In Vitro Fertilization-Embryo Transfer | 27.3 | 0 | 2 |
| Costs of medically assisted reproduction treatment at specialized fertility clinics in the Danish public health care system: results from a 5-year follow-up cohort study | 27.3 | 0 | 2 |
| Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers | 27.3 | 0 | 2 |
| 1995 assisted reproductive technology success rates: national summary and fertility clinic report. | 27.3 | 0 | 2 |
| 2006 Guidelines for Gamete and Embryo Donation | 27.3 | 0 | 2 |
| Elements to be considered in obtaining informed consent for ART. | 27.3 | 0 | 2 |
| Advanced maternal age as an indication for preimplantation genetic diagnosis (PGD)--the need for more judicious application in clinically assisted reproduction | 27.3 | 0 | 2 |
| Efficiency of changing the embryo transfer time from day 3 to day 2 among women with poor ovarian response: a prospective randomized trial | 27.3 | 0 | 2 |
| Rethinking the biological clock: eleventh-hour moms, miracle moms and meanings of age-related infertility | 27.3 | 0 | 2 |
| Cetrorelix in women with poor ovarian response in previous assisted reproduction cycles | 27.3 | 0 | 2 |
| Use of fetal oocytes in assisted reproduction | 27.3 | 0 | 2 |
| Optimizing natural fertility: a committee opinion | 27.3 | 0 | 2 |
| Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age. | 27.3 | 0 | 2 |
| Expectations for success in fertility treatment involving assisted reproduction | 27.3 | 0 | 2 |
| Reproductive medicine in transition: new developments in embryo transfer | 27.3 | 0 | 2 |
| Different perspectives of patients and health care professionals on the potential benefits and risks of blastocyst culture and multiple embryo transfer | 27.3 | 0 | 2 |
| Efficacy of intrauterine inseminations as a training modality for performing embryo transfer in reproductive endocrinology and infertility fellowship programs. | 27.3 | 0 | 2 |
| Annual report of Reproductive Endocrinology Committee, Japan Society of Obstetrics and Gynecology, 2013 | 27.3 | 0 | 2 |
| Evaluation of Ovarian Reserve Based on Hormonal Parameters, Ovarian Volume, and Antral Follicle Count in Women with Type 2 Diabetes Mellitus | 27.3 | 0 | 2 |
| Revised guidelines for human embryology and andrology laboratories | 27.3 | 0 | 2 |
| Age, oestradiol and blastocysts can predict success in natural cycle IVF-embryo transfer | 27.3 | 0 | 2 |
| With low ovarian reserve, Highly Individualized Egg Retrieval (HIER) improves IVF results by avoiding premature luteinization | 27.3 | 0 | 2 |
| High basal LH levels in combination with low basal FSH levels are associated with high success rates at assisted reproduction | 27.3 | 0 | 2 |
| Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An ana | 27.3 | 0 | 2 |
| Becoming a mother by non-anonymous egg donation: secrecy and the relationship between egg recipient, egg donor and egg donation child | 27.3 | 0 | 2 |
| AIDA for reproductive medicine and the fertility clinic | 27.3 | 0 | 2 |
| The interval transfer of a frozen-thawed embryo is more successful than a fresh embryo transfer for women undergoing IVF with recurrent implantation failure after cleavage stage embryo biopsy | 27.3 | 0 | 2 |
| Beyond the American Society for Reproductive Medicine transfer guidelines: how many cleavage-stage embryos are safe to transfer in women ≥43 years old? | 27.3 | 0 | 2 |
| Estimation of ovarian response using multiple predictors of ovarian reserve in women undergoing in vitro fertilization-embryo transfer | 27.3 | 0 | 2 |
| Economic implications of the Society for Assisted Reproductive Technology embryo transfer guidelines: healthcare dollars saved by reducing iatrogenic triplets | 27.3 | 0 | 2 |
| Successful pregnancy following a single fresh embryo transfer in a 45-year-old woman whose early follicular phase serum follicle stimulating hormone was 29 mIU/ml | 27.3 | 0 | 2 |
| Estrous cycle staging before mating led to increased efficiency in the production of pseudopregnant recipients without negatively affecting embryo transfer in mice | 27.3 | 0 | 2 |
| AIUM practice guideline for ultrasonography in reproductive medicine | 27.3 | 0 | 2 |
| Surveillance of congenital malformations in infants conceived through assisted reproductive technology or other fertility treatments | 27.3 | 0 | 2 |
| Ovarian reserve evaluation by anti-mullerian hormone in women undergoing laparoscopic cystectomy of endometrioma | 27.3 | 0 | 2 |
| Effects of cystectomy for ovary benign cyst on ovarian reserve and pregnancy outcome of in vitro fertilization-embryo transfer cycle | 27.3 | 0 | 2 |
| Effect of follicle stimulating hormone on the secretion of anti-mullerian hormone in the granulosa cells in patients with polycystic ovarian syndrome | 27.3 | 0 | 2 |
| Recommendations for practices utilizing gestational carriers: a committee opinion | 27.3 | 0 | 2 |
| Trust women to choose: a response to John a Robertson's 'Egg freezing and Egg banking: empowerment and alienation in assisted reproduction'. | 27.3 | 0 | 2 |
| Recombinant-follicle stimulating hormone is more effective than urinary human menopausal gonadotropin in ovarian hyperstimulation for assisted reproductive technology treatment | 27.3 | 0 | 2 |
| Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial | 27.3 | 0 | 2 |
| Assisted reproductive technology in Europe, 2013: results generated from European registers by ESHRE† | 27.3 | 0 | 2 |
| A combination of follicle stimulating hormone, estradiol and age is associated with the pregnancy outcome for women undergoing assisted reproduction: a retrospective cohort analysis | 27.3 | 0 | 2 |
| Indications for fertility preservation in women from malignant diseases to benign conditions to age-related fertility decline | 27.3 | 0 | 2 |
| Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type | 27.3 | 0 | 2 |
| Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Multicenter evaluation of the Access AMH antimüllerian hormone assay for the prediction of antral follicle count and poor ovarian response to controlled ovarian stimulation | 27.3 | 0 | 2 |
| In-vitro fertilization (IVF), embryo transfer (ET) and assisted reproduction in the State of Israel | 27.3 | 0 | 2 |
| Reply: Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer | 27.3 | 0 | 2 |
| Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer: where is the evidence? | 27.3 | 0 | 2 |
| Abstracts for 2018 Foundation for Reproductive Medicine Translational Reproductive Biology and Clinical Reproductive Endocrinology Conference | 27.3 | 0 | 2 |
| Egg Quality and Pregnancy Outcome in Young Infertile Women with Diminished Ovarian Reserve | 27.3 | 0 | 2 |
| Position statement on West Nile virus: a committee opinion | 27.3 | 0 | 2 |
| Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage | 27.3 | 0 | 2 |
| Egg donation model: an excellent way to isolate and analyze the impact of the male partner on assisted reproductive technology outcome | 27.3 | 0 | 2 |
| Application of seminal plasma to female genital tract prior to embryo transfer in assisted reproductive technology cycles (IVF, ICSI and frozen embryo transfer) | 27.3 | 0 | 2 |
| Misconduct in third-party assisted reproduction: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Re: Fertility Preservation for Men with Testicular Cancer: Is Sperm Cryopreservation Cost Effective in the Era of Assisted Reproductive Technology? | 27.3 | 0 | 2 |
| Disclosure of sex when incidentally revealed as part of preimplantation genetic testing (PGT): an Ethics Committee opinion | 27.3 | 0 | 2 |
| Ethical obligations in fertility treatment when intimate partners withhold information from each other: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Use of preimplantation genetic testing for monogenic defects (PGT-M) for adult-onset conditions: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Gender reassignment and assisted reproduction: An ethical analysis. Bristol Centre for Reproductive Medicine Ethics Advisory Committee | 27.3 | 0 | 2 |
| Shared-risk or refund programs in assisted reproduction. The Ethics Committee of the American Society for Reproductive Medicine | 27.3 | 0 | 2 |
| DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: A systematic review and meta-analysis | 27.3 | 0 | 2 |
| The effectiveness of sublingual progesterone administration during cryopreserved embryo transfer cycles: results of a matched follow-up study**Presented in part at the 51st Annual Meeting of the American Society for Reproductive Medicine, Seattle, Wa | 27.3 | 0 | 2 |
| Fertility preservation for age-related fertility decline | 27.3 | 0 | 2 |
| Egg freezing for fertility preservation and family planning: a nationwide survey of US Obstetrics and Gynecology residents | 27.3 | 0 | 2 |
| Large for gestational age and macrosomia in singletons born after frozen/thawed embryo transfer (FET) in assisted reproductive technology (ART) | 27.3 | 0 | 2 |
| Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved | 27.3 | 0 | 2 |
| Single Human Embryo Transfer in Assisted Reproduction Programs | 27.3 | 0 | 2 |
| Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART) | 27.3 | 0 | 2 |
| Trigger Time in Advanced Maternal Age Patients With Low AMH | 27.3 | 0 | 2 |
| Health in Childhood Following Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Clinical Cohort Study on the Endocrinology and Vaginal Microbiome of the Luteal Phase in Assisted Reproduction | 27.3 | 0 | 2 |
| The Effect of Embryo Culture Under Low Oxygen Tension on Pregnancy Rates | 27.3 | 0 | 2 |
| Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART) | 27.3 | 0 | 2 |
| Anti-mullerian Hormone (AMH) After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery: Clinical Trial | 27.3 | 0 | 2 |
| Anti-Mullerian Hormone (AMH) is a Marker for Ovarian Reserve. There Are Many Studies About AMH Changes in Ovarian Surgery, But Little is Known for Other Surgeries. We Seek to Investigate the Hormone Variations Before and After Uterine Artey Liga | 27.3 | 0 | 2 |
| Does the Embryo Transfer Technique Affect the Success of in Vitro Fertilization? | 27.3 | 0 | 2 |
| Aneuploidy Rate and Stimulation Protocol: Recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH | 27.3 | 0 | 2 |
| Clinical Measures of Ovarian Reserve in Predicting IVF Success | 27.3 | 0 | 2 |
| Abstracts for 2017 Foundation for Reproductive Medicine Translational Reproductive Biology and Clinical Reproductive Endocrinology Conference | 27.3 | 0 | 2 |
| What advice should we give our patients to preserve their fertility and avoid needing oocyte donation in the future? - A Social Fertility Preservation program | 27.3 | 0 | 2 |
| Safety data for the use of nasal human menopausal gonadotropins: a potential novel approach for fertility treatment | 27.3 | 0 | 2 |
| Elective single embryo transfer in women less than age 38 years reduces multiple birth rates, but not live birth rates, in United States fertility clinics | 27.3 | 0 | 2 |
| Correlation between Ovarian Reserve and Incidence of Ectopic Pregnancy after Fertilization and Embryo Transfer | 27.3 | 0 | 2 |
| Efficacy of Hypnosis During Embryo Transfer Procedure on Clinical Pregnancy Rate for Patients Undergoing Assisted Reproductive Technology IVF or ICSI | 27.3 | 0 | 2 |
| Delayed Embryo Transfer in Poor Responders | 27.3 | 0 | 2 |
| Biomarkers of Ovarian Reserve and Correlation With IVF Treatments | 27.3 | 0 | 2 |
| Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response. | 27.3 | 0 | 2 |
| A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment | 27.3 | 0 | 2 |
| Electro-acupuncture and Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Bed Rest or no Bed Rest? | 27.3 | 0 | 2 |
| Egg Freezing Pilot Study | 27.3 | 0 | 2 |
| Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age | 27.3 | 0 | 2 |
| EmbryoGlue as an Embryo Transfer Medium | 27.3 | 0 | 2 |
| The Accuracy of Endometrial Ultrasound to Predict Implantation | 27.3 | 0 | 2 |
| Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer | 27.3 | 0 | 2 |
| Influence of Post-thaw Embryo Culture Interval on Assisted Reproduction Success Rates | 27.3 | 0 | 2 |
| Comparison of Oocyte Maturation Trigger Using Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin versus hCG Alone in Assisted Reproduction Technology Cycles | 27.3 | 0 | 2 |
| Blastocyst Euploidy Assessment and Conditioned embryO traNsfer | 27.3 | 0 | 2 |
| Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism | 27.3 | 0 | 2 |
| Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve | 27.3 | 0 | 2 |
| Effect of Follicular Phase Acupuncture on Anti-Mullerian Hormone in Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF And The Effect on Assisted Reproduction Outcome | 27.3 | 0 | 2 |
| Embryo Kinetics and Stimulation Protocol: Recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH | 27.3 | 0 | 2 |
| A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Con | 27.3 | 0 | 2 |
| Predictive Value of Mid-luteal Serum Progesterone Levels in Egg Donation Cycles | 27.3 | 0 | 2 |
| Antimullerian Hormone in Endometriomas | 27.3 | 0 | 2 |
| Study of Follicle Stimulating Hormone (FSH) Receptor in Women With Low Antral Follicle Count | 27.3 | 0 | 2 |
| Acupuncture for Treatment of Patients With Poor Ovarian Response | 27.3 | 0 | 2 |
| Newborns From Patients Treated With ART (Assisted Reproductive Technology) | 27.3 | 0 | 2 |
| Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment | 27.3 | 0 | 2 |
| Comparison of Embryo Transfer in Egg Donation Recipients With Transvaginal and Transabdominal Ultrasound | 27.3 | 0 | 2 |
| Blastocyst Culture Using Time-lapse in Good Prognosis IVF Patients and Elective Single Embryo Transfer | 27.3 | 0 | 2 |
| Evaluating the AMH Levels During Natural Cycle | 27.3 | 0 | 2 |
| Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET | 27.3 | 0 | 2 |
| Study Comparing Outcomes Between Conventional IVF and a "Freeze-all"-Strategy in Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Antimullerian Hormone Versus Antral Follicle Count for Determination of Gonadotrophin Dosing in IVF | 27.3 | 0 | 2 |
| In vitro fertilization-embryo transfer (IVF-ET) in the United States: 1990 results from the IVF-ET Registry. Medical Research International. Society for Assisted Reproductive Technology (SART), The American Fertility Society | 27.3 | 0 | 2 |
| In vitro fertilization-embryo transfer (IVF-ET) in the United States: 1989 results from the IVF-ET Registry. Medical Research International, Society for Assisted Reproductive Technology, The American Fertility Society | 27.3 | 0 | 2 |
| In vitro fertilization-embryo transfer in the United States: 1988 results from the IVF-ET Registry. Medical Research International. Society for Assisted Reproductive Technology. American Fertility Society | 27.3 | 0 | 2 |
| Differential indications for surgical technics in reproductive medicine--microsurgery, in vitro fertilization and embryo transfer, gamete intrafallopian transfer and tubal embryo transfer | 27.3 | 0 | 2 |
| In vitro fertilization and other assisted reproduction. Vth World Congress on In Vitro Fertilization and Embryo Transfer. Norfolk, Virginia, April 5-10, 1987. Proceedings | 27.3 | 0 | 2 |
| The functional ovarian reserve in assisted reproduction. A clinical dilemma | 27.3 | 0 | 2 |
| Evaluating ovarian reserve: follicle stimulating hormone and oestradiol variability during cycle days 2-5 | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States and Canada: 1994 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Methodology of human embryo transfer following assisted reproduction | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States and Canada: 1993 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Exogenous follicle stimulating hormone ovarian reserve test (EFORT): a simple and reliable screening test for detecting 'poor responders' in in-vitro fertilization | 27.3 | 0 | 2 |
| Reproductive medicine and assisted reproduction--present status and perspectives in the Czech Republic | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1997 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Blastocyst culture and transfer in a assisted reproduction programme | 27.3 | 0 | 2 |
| The genetic sonogram: its use in the detection of chromosomal abnormalities in fetuses of women of advanced maternal age | 27.3 | 0 | 2 |
| A rational basis for antiphospholipid antibody testing and selective immunotherapy in assisted reproduction: a rebuttal to the American Society for Reproductive Medicine Practice opinion. American Society for Reproductive Immunology Antiphospholipid | 27.3 | 0 | 2 |
| Long GnRH-agonist protocol in an IVF program. Is it appropriate for women with normal FSH levels and high FSH/LH ratios? | 27.3 | 0 | 2 |
| Gonadotropin and body mass index: high FSH levels in lean, normally cycling women | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI) | 27.3 | 0 | 2 |
| Embryo transfer: a critical step in assisted reproduction | 27.3 | 0 | 2 |
| Assisted Reproductive Technology in the United States and Canada: 1995 Results Generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| First established pregnancy and birth after induction of ovulation with recombinant human follicle stimulating hormone during in vitro fertilization-embryo transfer and intracytoplasmic sperm injection | 27.3 | 0 | 2 |
| The Impact of Lifestyle on Sperm Telomere Length and Telomerase Activity in Men Undergoing IVF Treatments | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1996 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction | 27.3 | 0 | 2 |
| The role of assisted hatching in in vitro fertilization: a review of the literature. A Committee opinion | 27.3 | 0 | 2 |
| Ovarian tissue and oocyte cryopreservation | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Preimplantation genetic diagnosis | 27.3 | 0 | 2 |
| Guidelines on number of embryos transferred | 27.3 | 0 | 2 |
| Revised guidelines for human embryology and andrology laboratories | 27.3 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons | 27.3 | 0 | 2 |
| [Towards a single embryo transfer: predictive value of uterine and embryological parameters in assisted reproduction outcome] | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies | 27.3 | 0 | 2 |
| Elective single embryo transfer in assisted reproduction | 27.3 | 0 | 2 |
| Graduated Embryo Score and soluble human leukocyte antigen-G expression improve assisted reproductive technology outcomes and suggest a basis for elective single-embryo transfer | 27.3 | 0 | 2 |
| FSH levels in the menopausal or castrated women afflicted with breast cancer in an advanced phase. Influence of adrenal interventions | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Removal of cervical mucus prior to embryo transfer improves pregnancy rates in women undergoing assisted reproduction | 27.3 | 0 | 2 |
| Health economic consequences of the choice of follicle stimulating hormone alternatives in IVF treatment | 27.3 | 0 | 2 |
| Assisted reproductive technology practice patterns and the impact of embryo transfer guidelines in the United States | 27.3 | 0 | 2 |
| The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society for Assisted Reproductive Technology/American Society for Reproductive Medicine recommendation | 27.3 | 0 | 2 |
| Ovarian Reserve and Ankylosing Spondylitis | 27.3 | 0 | 2 |
| Guidelines for advertising by ART programs | 27.3 | 0 | 2 |
| Measurement of anti-mullerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid | 27.3 | 0 | 2 |
| Guidelines on the number of embryos transferred | 27.3 | 0 | 2 |
| Guidelines for advertising by ART programs | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI) | 27.3 | 0 | 2 |
| Blastocyst production and transfer in clinical assisted reproduction | 27.3 | 0 | 2 |
| Shared-risk or refund programs in assisted reproduction | 27.3 | 0 | 2 |
| Assisted reproduction in male cancer survivors: fertility treatment and outcome in 67 couples | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile | 27.3 | 0 | 2 |
| Would legislation imposing single embryo transfer be a feasible way to reduce the rate of multiple pregnancies after IVF treatment? | 27.3 | 0 | 2 |
| Assisted reproductive technology has been detrimental to academic reproductive endocrinology and infertility | 27.3 | 0 | 2 |
| Assisted reproductive technology has been detrimental to academic reproductive endocrinology and infertility: depth of the problem and possible solutions | 27.3 | 0 | 2 |
| Elective single embryo transfer versus double embryo transfer in assisted reproduction | 27.3 | 0 | 2 |
| Single embryo transfer in IVF treatment | 27.3 | 0 | 2 |
| Age-related fertility decline: a committee opinion | 27.3 | 0 | 2 |
| Effect of embryo transfer number on singleton and twin implantation pregnancy outcomes after assisted reproductive technology | 27.3 | 0 | 2 |
| Response by the leadership of the Society of Assisted Reproductive Technology (SART) to the article “Assisted Reproduction and Choices in the Biotech Age” | 27.3 | 0 | 2 |
| Age-related fertility decline: a committee opinion | 27.3 | 0 | 2 |
| Guidelines for reducing the risk of viral transmission during fertility treatment | 27.3 | 0 | 2 |
| Anti-phospholipid antibodies do not affect IVF success | 27.3 | 0 | 2 |
| Genetic considerations related to intracytoplasmic sperm injection (ICSI) | 27.3 | 0 | 2 |
| The role of assisted hatching in in vitro fertilization: a review of the literature. A Committee opinion | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Ovarian tissue and oocyte cryopreservation | 27.3 | 0 | 2 |
| Revised guidelines for human embryology and andrology laboratories | 27.3 | 0 | 2 |
| Acupuncture intervention combined with assisted reproductive technology: its different effects at different time points during the in vitro fertilization-embryo transfer course | 27.3 | 0 | 2 |
| Antral follicle count in clinical practice: building the bridge from ovarian reserve to in vitro fertilization outcome | 27.3 | 0 | 2 |
| Effect of the new legislation and single-embryo transfer policy in Turkey on assisted reproduction outcomes: preliminary results | 27.3 | 0 | 2 |
| Changing attitudes towards non-invasive aneuploidy screening at advanced maternal age in a German tertiary care center | 27.3 | 0 | 2 |
| A skewed sex ratio following blastocyst culture is a consequence of embryo grading systems that prioritise male embryos for transfer | 27.3 | 0 | 2 |
| Committee opinion: role of tubal surgery in the era of assisted reproductive technology | 27.3 | 0 | 2 |
| A persistent misperception: assisted reproductive technology can reverse the “aged biological clock” | 27.3 | 0 | 2 |
| Practice patterns and outcomes with the use of single embryo transfer in the United States | 27.3 | 0 | 2 |
| Incorporation of a follicle stimulating hormone used for embryo transfer in cattle into multilamellar liposomes | 27.3 | 0 | 2 |
| Recommendations for practices utilizing gestational carriers: an ASRM Practice Committee guideline | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile: a committee opinion | 27.3 | 0 | 2 |
| Results after assisted reproduction at a public fertility clinic | 27.3 | 0 | 2 |
| Reproductive endocrinology: vitamin D and AMH levels are correlated in human adults | 27.3 | 0 | 2 |
| Position statement on West Nile virus: a committee opinion | 27.3 | 0 | 2 |
| Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Guidelines on number of embryos transferred | 27.3 | 0 | 2 |
| Effect of different embryo transfer strategies on the outcome of assisted reproduction | 27.3 | 0 | 2 |
| Re: "Estimation of the contribution of non-assisted reproductive technology ovulation stimulation fertility treatments to US singleton and multiple births" | 27.3 | 0 | 2 |
| Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti‐Müllerian hormone and small antral follicle count using three‐dimensional ultrasound | 27.3 | 0 | 2 |
| Criteria for number of embryos to transfer: a committee opinion | 27.3 | 0 | 2 |
| Uterine contractile activity at Embryo Transfer – as a new pharmacotherapeutic target in assisted reproduction | 27.3 | 0 | 2 |
| Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan | 27.3 | 0 | 2 |
| AIUM Practice Guideline for the Performance of a Focused Reproductive Endocrinology and Infertility Scan | 27.3 | 0 | 2 |
| Reply: Endometrioma excision and ovarian reserve: do assessments by antral follicle count and anti-Müllerian hormone yield contradictory results? | 27.3 | 0 | 2 |
| Endometrioma excision and ovarian reserve; do assessments by antral follicle count and anti-Müllerian hormone yield contradictory results? | 27.3 | 0 | 2 |
| Ovarian reserve and anti-Mullerian hormone (AMH) in mothers of dizygotic twins | 27.3 | 0 | 2 |
| Effects of Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response and Premature Ovarian Insufficiency | 27.3 | 0 | 2 |
| Comparing the Effect of Laparoscopic Supracervical and Total Hysterectomy for Uterine Fibroids on Ovarian Reserve by Assessing Serum Anti-Mullerian Hormone Levels: A Prospective Cohort Study | 27.3 | 0 | 2 |
| The effect of isotretinoin on ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with acne | 27.3 | 0 | 2 |
| Fertility preservation for age-related fertility decline – Authors' reply | 27.3 | 0 | 2 |
| Fertility preservation for age-related fertility decline | 27.3 | 0 | 2 |
| Psychosocial factors in reproductive medicine | 27.3 | 0 | 2 |
| Role of ovarian reserve markers, antimüllerian hormone and antral follicle count, as aneuploidy markers in ongoing pregnancies and miscarriages | 27.3 | 0 | 2 |
| Surgery Before Embryo Transfer in ERROR (Endometrioma Related Reduction in Ovarian Reserve) | 27.3 | 0 | 2 |
| Use of reproductive technology for sex selection for nonmedical reasons | 27.3 | 0 | 2 |
| Processing of semen by density gradient centrifugation selects spermatozoa with longer telomeres for assisted reproduction techniques | 27.3 | 0 | 2 |
| [Assisted Reproductive Technology in Female Transplant Recipients: Experience of a Reproductive Medicine Unit and Literature Review] | 27.3 | 0 | 2 |
| Successful pregnancy following assisted reproduction and transmyometrial embryo transfer in a patient with anatomical distortion of the cervical canal | 27.3 | 0 | 2 |
| Validity for assisted hatching on pregnancy rate in assisted reproductive technology: Analysis based on results of Japan Assisted Reproductive Technology Registry System 2010 | 27.3 | 0 | 2 |
| Should all embryos be cultured to blastocyst for advanced maternal age women with low ovarian reserve: a single center retrospective study | 27.3 | 0 | 2 |
| The combination of dehydroepiandrosterone, transdermal testosterone, and growth hormone as an adjuvant therapy in assisted reproductive technology cycles in patients aged below 40 years with diminished ovarian reserve | 27.3 | 0 | 2 |
| Evaluation of ovarian reserve using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: Preliminary study | 27.3 | 0 | 2 |
| [Influence of assisted reproductive technology and related factors on chromosomal abnormalities in early spontaneous abortions] | 27.3 | 0 | 2 |
| Preimplantation genetic testing in assisted reproductive technology | 27.3 | 0 | 2 |
| ASRM standard embryo transfer protocol template: a committee opinion | 27.3 | 0 | 2 |
| The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study | 27.3 | 0 | 2 |
| Compassionate transfer: patient requests for embryo transfer for nonreproductive purposes | 27.3 | 0 | 2 |
| Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion | 27.3 | 0 | 2 |
| A systematic review on concurrent aneuploidy screening and preimplantation genetic testing for hereditary disorders: What is the prevalence of aneuploidy and is there a clinical effect from aneuploidy screening? | 27.3 | 0 | 2 |
| Elective egg freezing for age-related fertility decline | 27.3 | 0 | 2 |
| Reporting assisted reproductive technology success rates on Australian and New Zealand fertility clinic websites | 27.3 | 0 | 2 |
| An Economic Analysis of Aneuploidy Screening of Oocytes in Assisted Reproduction in Germany | 27.3 | 0 | 2 |
| Minimum standards for practices offering assisted reproductive technologies: a committee opinion | 27.3 | 0 | 2 |
| Preimplantation genetic testing in assisted reproduction technology | 27.3 | 0 | 2 |
| Live birth rate comparison of three controlled ovarian stimulation protocols for in vitro fertilization-embryo transfer in patients with diminished ovarian reserve after endometrioma cystectomy: a retrospective study | 27.3 | 0 | 2 |
| Assisted Reproductive Technology and the Reproductive Endocrinology and Infertility Specialist in the U.S. Military | 27.3 | 0 | 2 |
| Women's attitudes and beliefs about using fertility preservation to prevent age-related fertility decline-A two-year follow-up | 27.3 | 0 | 2 |
| Serum anti-Mullerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve | 27.3 | 0 | 2 |
| Eleven healthy live births: a result of simultaneous preimplantation genetic testing of α- and β-double thalassemia and aneuploidy screening | 27.3 | 0 | 2 |
| Re: Assisted Reproductive Technology Outcomes in Female-to-Male Transgender Patients Compared with Cisgender Patients: A New Frontier in Reproductive Medicine | 27.3 | 0 | 2 |
| Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial | 27.3 | 0 | 2 |
| Herbal fertility treatments used in North America from colonial times to 1900, and their potential for improving the success rate of assisted reproductive technology | 27.3 | 0 | 2 |
| Outcomes of in vitro fertilization-embryo transfer in women with diminished ovarian reserve after growth hormone pretreatment | 27.3 | 0 | 2 |
| Elective Single Embryo Transfer in the Setting of Funded In Vitro Fertilization: Two Years' Experience in an Ontario Hospital-Based Fertility Clinic | 27.3 | 0 | 2 |
| Curative effect of assisted reproduction technology by Traditional Chinese Medicine multi-channel interventional therapy on 95 cases of in vitro fertilization and embryo transfer failure | 27.3 | 0 | 2 |
| Androgenicity and fertility treatment in women with unexplained infertility | 27.3 | 0 | 2 |
| Assisted reproductive technology outcomes in female-to-male transgender patients compared with cisgender patients: a new frontier in reproductive medicine | 27.3 | 0 | 2 |
| Assessment of Turkey IVF (In Vitro Fertilization) websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines | 27.3 | 0 | 2 |
| The effect of acupuncture on anti-mullerian hormone and assisted reproduction outcome in Polycystic Ovary Syndrome patients undergoing in vitro fertilization | 27.3 | 0 | 2 |
| Preimplantation Genetic Testing of Aneuploidy by Next Generation Sequencing: Association of Maternal Age and Chromosomal Abnormalities of Blastocyst | 27.3 | 0 | 2 |
| Assessment of the Role of the Anti-Mullerian Hormone, Luteinizing Hormone/Follicle Stimulating Hormone Ratio in the Diagnosis of Polycystic Ovary Syndrome in Sudanese Women | 27.3 | 0 | 2 |
| Second-generation preimplantation genetic testing for aneuploidy in assisted reproduction: a SWOT analysis | 27.3 | 0 | 2 |
| Application of embryo biopsy and sex determination via polymerase chain reaction in a commercial equine embryo transfer program in Argentina | 27.3 | 0 | 2 |
| Preimplantation Genetic Testing for Aneuploidy Improves Clinical, Gestational, and Neonatal Outcomes in Advanced Maternal Age Patients Without Compromising Cumulative Live-Birth Rate | 27.3 | 0 | 2 |
| Abstracts presented at the 2019 Foundation for Reproductive Medicine Conference on Translational Reproductive Biology and Clinical Reproductive Endocrinology | 27.3 | 0 | 2 |
| Drug-free in-vitro activation of follicles for infertility treatment in poor ovarian response patients with decreased ovarian reserve | 27.3 | 0 | 2 |
| The ethics of fertility treatment for same-sex male couples: Considerations for a modern fertility clinic | 27.3 | 0 | 2 |
| The Effect of Assisted Hatching on Live Birth Rate Following Fresh Embryo Transfer in Advanced Maternal Age | 27.3 | 0 | 2 |
| [Medically Assisted Reproduction in Natural Cycle: Outcome Evaluation of a Reproductive Medicine Department] | 27.3 | 0 | 2 |
| Severity of Diminished Ovarian Reserve and Chance of Success with Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Corticosteroids Prior to Embryo Transfer in Assisted Reproduction in Women with Crohn's Disease and Ulcerative Colitis - A Nationwide Cohort Study | 27.3 | 0 | 2 |
| [Exploration of the process of prenatal screening and diagnosis for women with advanced maternal age based on results of 351 cases of fetal chromosomal abnormalities] | 27.3 | 0 | 2 |
| A counterintuitive lesson in family planning? Patience first: taking a "gap year" after live birth from assisted reproductive technology before frozen embryo transfer is performed | 27.3 | 0 | 2 |
| The impact of the localisation of endometriosis lesions on ovarian reserve and assisted reproduction techniques outcomes | 27.3 | 0 | 2 |
| Age effect on in vitro fertilization pregnancy mediated by anti-Mullerian hormone (AMH) and modified by follicle stimulating hormone (FSH) | 27.3 | 0 | 2 |
| [Prediction of clinical outcomes of patients with surplus cleavage-stage embryos for blastocyst culture after D3 embryo transfer] | 27.3 | 0 | 2 |
| Does preimplantation genetic testing for aneuploidy really improve IVF outcomes in advanced maternal age patients without compromising cumulative live-birth rate? | 27.3 | 0 | 2 |
| Zygotic splitting following embryo biopsy: a cohort study of 207 697 single-embryo transfers following IVF treatment | 27.3 | 0 | 2 |
| Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion | 27.3 | 0 | 2 |
| EUropean REcommendations for female FERtility preservation (EU-REFER): A joint collaboration between oncologists and fertility specialists | 27.3 | 0 | 2 |
| Use of Frozen Embryo Transfer During Fertility Treatment and Risk of Childhood Cancer | 27.3 | 0 | 2 |
| Use of Frozen Embryo Transfer During Fertility Treatment and Risk of Childhood Cancer-Reply | 27.3 | 0 | 2 |
| A novel mathematical model of true ovarian reserve assessment based on predicted probability of poor ovarian response: a retrospective cohort study | 27.3 | 0 | 2 |
| Reproductive success of assisted reproductive technology in couples with chromosomal abnormalities | 27.3 | 0 | 2 |
| Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer | 27.3 | 0 | 2 |
| Transfer of embryos with positive results following preimplantation genetic testing for monogenic disorders (PGT-M): experience of two high-volume fertility clinics | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion | 27.3 | 0 | 2 |
| A Chinese practice guideline of the assisted reproductive technology strategies for women with advanced age | 27.3 | 0 | 2 |
| Re: Egg Donation Model: An Excellent Way to Isolate and Analyze the Impact of the Male Partner on Assisted Reproductive Technology Outcome | 27.3 | 0 | 2 |
| Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve | 27.3 | 0 | 2 |
| Exposure to Fine Particulate Matter and Ovarian Reserve Among Women from a Fertility Clinic | 27.3 | 0 | 2 |
| Endometrial thickness on the day of embryo transfer is a poor predictor of IVF treatment outcome | 27.3 | 0 | 2 |
| Elective egg freezing and male support: a qualitative study of men's roles in women's fertility preservation | 27.3 | 0 | 2 |
| An economic analysis of preimplantation genetic testing for aneuploidy by polar body biopsy in advanced maternal age | 27.3 | 0 | 2 |
| Performance of preimplantation genetic testing for aneuploidy in IVF cycles for patients with advanced maternal age, repeat implantation failure, and idiopathic recurrent miscarriage | 27.3 | 0 | 2 |
| A novel de novo partial xq duplication in a girl with short stature, nonverbal learning disability and diminished ovarian reserve - effect of growth hormone treatment and fertility preservation strategies: a case report and up-to-date review | 27.3 | 0 | 2 |
| Role of aneuploidy screening in preimplantation genetic testing for monogenic diseases in young women | 27.3 | 0 | 2 |
| Prognostic role of preimplantation genetic testing for aneuploidy in medically indicated fertility preservation | 27.3 | 0 | 2 |
| Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum | 27.3 | 0 | 2 |
| Evaluation of the effect of the elective blastocyst-stage embryo transfer and freezing strategy on the abandonment of frozen embryos under the Taiwan National Assisted Reproduction Act | 27.3 | 0 | 2 |